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Chapter 1 
General introduction 
 
 
1.1. Background 
Oral dosage forms are the most common pharmaceutical formulations. To be effective 
and reach their site of action, the drug has to solubilize in gastrointestinal fluids and permeate  
membranes in the gastrointestinal tract [1][2]. The active pharmaceutical ingredients (APIs) 
according to Biopharmaceutical Classification System can be classified in class I, II, III and 
IV, where the class II and IV drugs exhibit low water solubility. The absorption of most of 
these APIs will be limited by their solubility or their dissolution rate [1][3][4].  
The management of these poorly water-soluble drugs is one of the major challenges in 
the field of pharmaceutics. Many techniques enable to improve the solubility or to increase the 
surface area available for the dissolution enhancement of poorly water-soluble active 
pharmaceutical ingredients (APIs) through chemical or physical modifications, for example by 
using soluble prodrugs and salts, changing the particle size, the crystal lattice (including 
amorphization and polymorphism), and by using complexes of the drug with adequate ligands.  
A key strategy used to address solubility issues is the formulation of amorphous dispersions of 
challenging  APIs [3][5][6]. 
Amorphous solid dispersions (ASDs) are one-phase solid systems that contain an 
amorphous drug stabilized in one or more polymeric carriers. The amorphous form is a 
disordered structure with a high free energy. This form presents advantageous 
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biopharmaceutical characteristics compared to the crystalline form. Targeted is especially , an 
improvement in the apparent solubility, dissolution rate, and bioperformance for oral delivery 
[5][7].  
The degree of drug dispersion can be reduced to the molecular level in ASDs and the 
presence of hydrophilic carrier leads to improved wettability of the system and possibly an 
increase in apparent solubility, due to higher free energy for solubility enhancement based on 
changes in enthalpy and entropy, as compared with the crystalline form [1][7]. There are three 
types of ASDs depending on the physical state of the API in the matrix. Thus, a glassy 
suspension is obtained if the drug is dispersed in an amorphous state and a crystalline 
suspension is given when the drug remains in the form of fine crystalline particles; finally, a 
glass solution may obtained if the drug is dispersed at a molecular level [4][8].  
The selection of the manufacturing process is very important for the ASD. In general, 
ASDs are prepared by heat based methods and solvent based methods due their high efficacy, 
low costs, fewer types of materials involved and a relatively easy way to scale up [3][9]. A 
possible challenge during the manufacturing process is to avoid the formation of large drug 
clusters and to prevent any phase separation [9][10][11]. 
ASDs have proven to be superior to other techniques for oral delivery of poorly soluble 
drugs, however there is still the concern about thermodynamic instability. ASDs are metastable 
systems and bear the risk of instability during their shelf life. The manufacture process also 
influences the physical stability according to thermal history, particle morphology, and 
nucleation process produced by different methods [10][12].  
The molecular processes of phase separation as well as crystallization from amorphous 
material are complex and mobility in the glass state plays an important role. Relaxation of 
amorphous materials take place on different time scales, from primary diffusive (α-relaxation) 
to secondary local relaxation such as Johari-Goldstein relaxations (β-relaxation). While α-
relaxation becomes very slow in the glass state, it is mostly the secondary relaxations that are 
relevant for crystallization from amorphous state [11]–[14]. Once crystallization starts, it 
continues to reduce the system's free energy [15][16][17]. Thus, thermodynamics is the driver 
for physical change and molecular mobility is a facilitator, while surface effects can act as 
modulators, and heterogeneities as amplifiers of crystallization [18]. 
Despite the general success and advanced knowledge of ASD, as a standard formulation 
technique for poorly soluble drugs, there are still knowledge gaps, which concern strategies to 
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accelerate the development and improve performance of ASD [5][14]. Advancement can be 
expected, for example in the field of analytical characterization and regarding an improved 
understanding of formulation microstructures. Among the different analytical tools, the image-
based methods are particularly becoming relevant nowadays to provide direct insight from 
phase separation [19] and homogeneity [20][21]. 
The chemical imaging involves a sophisticated analytical technique for acquisition of 
images and spectra that contain the chemical information [21], which typically enables to study 
the spatial distribution of one or all formulation components [22]. Images can be acquired at 
the surface and in the bulk using different electron microscopy techniques, such as, 
transmission electron microscopy (TEM) and scanning electron microscopy (SEM) with 
energy dispersive X-ray spectroscopy (EDS) [17][24][25]. Alternatively the images can also 
be captured by vibrational spectroscopic techniques with appropriate optics, such as Raman 
[22][26][27], near infrared (NIR) or terahertz spectroscopy [18].  
Depending on the imaging method employed, it can be possible to obtain a clear visual 
result; nevertheless, it is usually difficult to achieve direct insight just from direct visual 
assessment of the obtained images. The image displays generally a complex cluster structure 
that is difficult to compare and to interpret at a specific length scale. Therefore, there is often 
a need of data processing once images are obtained in order to extract relevant structural data 
from solid dosage forms. However, it can be even more attractive to apply a mathematical 
model for characterization of heterogeneous physical structures such as fractals. 
Fractal is a concept of non-classical geometry proposed by Mandelbrot [27] to describe 
spatially and temporally, objects, systems, and phenomena [28]. Fractal dimensions provide 
here information about the irregularities of the system. In general, a high difference between 
the Euclidean dimension and the fractal dimension indicates a high level of irregularities of the 
studied system [29]. An essential concept of fractal theory is self-similarity, where the random 
chaotic irregularities present in a heterogeneous complex have often a type of fractal order 
across scales. This self-similarity is possible to be expressed mathematically as the range of 
magnification where the structure of a system keeps a similar pattern and therefore a constant 
fractal dimension [30]–[32]. 
Since fractals are ubiquitous in nature, the concept of fractals has been used in various 
scientific fields, including pharmaceutical sciences in which many different types of disordered 
or disordered systems or chaotic systems can be described by the theory. Applying the concept 
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of fractal time series analysis bring benefits to the management of chaotic and random systems, 
developing an atomic level understanding of different solid systems [33]–[36].  
To experimentally determine fractal dimensions, different techniques can be used. The 
best known box-counting method was developed for this purpose and can be used to quantify 
simultaneously porous channels and surface structures [37]. For solid pharmaceutical dosage 
forms, the irregularity degree of a subject can be highly abstracted into a non-integer fractal 
dimensional value (Df). The Df values may describe objects in a three-dimensional Euclidean 
space such as solids or porous structures but also surfaces can be studied. Thus, particle 
geometry can be assessed as well as surface roughness, particles shape, and size and the degree 
of spatial complexity [32][37]. 
Fractal geometry provides insights into the microstructure formed during a 
manufacturing process that cannot be otherwise obtained by conventional analytical 
approaches [30][37]. Interesting is in particular , the multifractal spectrum that can be used to 
provide information on the subtle geometrical properties of a fractal object, which cannot be 
otherwise fully described by a single fractal dimension [36][38]. The formalisms of 
multifractals express a generalized fractal dimension (Dq) and a moment order (q) that is a 
number within [-; +] interval extracting characteristics of the cluster distribution [39]. The 
multifractal spectra or the generalized dimension can be restricted to three values of particular 
interest D0, D1 and D2. Herein, D0 is the “classical box-counting dimension” also called the 
“capacity” dimension; D1 refers to an information dimension (related to Shannon’s measure of 
entropy) and characterizes the degree of disorder in a distribution. Finally, D2 is named 
“correlation” dimension so it indirectly marks a degree of clustering [39]–[43]. In the case of 
monofractal systems, D0= D1= D2, whereas on the other hand, different values D0≥ D1≥ D2 
indicate a multifractal system [39]. 
 
1.2. Motivation and objectives  
As it has been explained in the previous section, despite the success of ASDs, there is 
a need for improved tools able to provide a better understanding of these complex disordered 
systems and that should help predicting the stability behavior of ASDs. The application of these 
tools would enable a more efficient and faster development process, while ensuring a high-
quality of ASDs. 
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Hence, the general objective of this PhD thesis is to develop a coupled image based 
analytical tool linked to fractal approach, to enable study of the microstructure and to improve 
the process understanding of solid pharmaceutical formulations containing amorphous APIs. 
This thesis is divided into individual chapters which introduce the approach for microstructural 
characterization of these complex formulations. 
A first specific objective of this thesis is to introduce the fractal analysis for evaluation 
of drug distribution in ASDs by considering the approach of multifractal geometry. There is a 
specific aim to evaluate the impact of the addition of urea on the ASDs microstructure, once 
this excipient has shown promise for reducing the manufacture temperature as well as to 
improve drug release.  
Given that physical stability is a major concern about amorphous materials, since the 
amorphous drug in ASDs is prone to revert to its crystalline form. A second objective of the 
present thesis was to evaluate if the fractal analysis based on energy dispersive X-ray imaging 
can provide the means to identify early signs of physical instability from ASDs, which are 
typically not detected by standard methods like X-ray powder diffraction. 
Finally, another aim of the present work was to apply the multifractal data analysis for 
assessing the impact of different manufacturing techniques on the microstructure and 
performance of the obtained ASDs. 
  
 
Chapter 2 
General results and discussion 
 
 
This chapter summarizes the general results and discussion of the microstructural study 
via fractal geometry based on chemical imaging to gain insights concerning properties and 
performance of ASDs. 
It is evident from the literature that SEM-EDS is a most commonly used technique for 
representation of elemental composition from micro-scale surfaces, with a detection limit of 
approximately 0.1% [44]. Since SEM-EDS application focusses on elemental specific 
localization and distribution on the compact surface, model drugs that contain Cl atoms were 
selected. Such halogen atoms are generally well detected by SEM-EDS given that their 
elevated atomic number facilitates relatively higher X-ray scattering intensity in organic 
molecules. Specificity of the analytical method was given because the Cl atoms were only 
present in the drug molecules but not in any of the excipients used.  
The images obtained from SEM-EDS by the naked eye can barely provide insights 
beyond the finding of an absent larger-scale phase separation. For a more refined cluster 
analysis, this work introduced the multifractal approach. 
2.1. Multifractal analysis for drug distribution in ASDs  
The multifractal analysis was employed as a tool to quantify the complexity and spatial 
heterogeneity of compounds in ASDs. As previously mentioned, the drug can be incorporated 
differently in a matrix dependent on the type of the amorphous formulation. Drug clusters can 
exhibit very different space coverage and the degree of disorder and level of clustering can 
show differences.  
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ASDs were prepared using HPMCAS-LF and different drugs: amlodipine (AML), 
felodipine (FEL), glybenclamide (GLY), and indomethacine (IND). The multifractal analysis 
showed that the evolution of Dq versus q for the formulations AML10 (Amlodipine 10% w/w), 
FEL10, GLY10, and IND10 displayed sigma-shape where Dq decreased with higher values of 
q. This showed that the multifractal approach did not introduce any unnecessary complication 
because a simpler monofractal model would be clearly inadequate, as it would assume a single 
constant fractal dimension along different values of q.  
It was interesting to investigate the specific influences of given compounds on the 
multifractal dimensions. The results showed that the obtained fractal dimensions were 
influenced by drug loading: rising drug concentrations increased the different dimensions 
indicating a higher space coverage (D0), higher dimension of disorder (D1), and higher 
correlation dimension (D2), which in turn suggested a lower degree of clustering. 
The observed effect of compound was also statistically analyzed at a reference drug 
load of 10% (w/w). The API effect in D0 showed a pronounced difference between AML-FEL 
and FEL-IND. An interpretation of this result was that molecular interactions of the compound 
with HPMC-AS would define a particular microstructure of how drug clusters form in an 
ASDs. For D1 and D2 APIs were obviously affecting in their particular way the microstructure 
of the SDs even though the trends in changes of fractal dimensions were quite comparable.  
Any simpler assumption of a homogenous drug distribution in SDs or a distribution that can 
be described as a monofractal system would fall short in light of the results obtained. 
To extend the multifractal approach to more complex systems, ternary mixtures with a 
concentration of 5%w/w urea were analyzed. For chemical imaging, this approach resulted in 
“pseudo-binary images”. The multifractal analysis of API distribution indicated a lower 
generalized dimension on formulation with urea, corresponding to a lower space coverage (D0), 
lower heterogeneity (D1), and higher clustering level (D2). In contrast to all other APIs, ASDs 
of IND and polymer had lower values of D0, D1 and D2 than IND formulations with added urea.  
From a mechanistic perspective, urea could have different effects. Owing to its particular 
structure, urea has the ability to interfere with hydrogen bonding. An influence of urea on 
hydrogen bonding patterns in solid dispersions is therefore interesting but would require 
additional spectroscopic studies for clarification. There could be also general effects of urea on 
the cluster structure so that a simple dilution of polymer could have played a role in the 
observed fractal dimensions of the ternary mixtures. 
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2.2. Multifractal approach in the early stages of physical 
instability  
The metastable character of ASD is a hurdle for their development because of re-
crystallization. It is particularly critical when such physical instability is only detected late in 
pharmaceutical development, whereas an early identification of kinetically unstable 
formulations is less problematic in a screening phase. Accordingly, there is a tremendous 
interest in early identification of drug phase separation and re-crystallization from amorphous 
state. Based on the hypothesis that multifractals can be helpful to early detect instability in 
amorphous drug formulations, a stability study was performed, focusing on the early stage of 
stability testing, which did not reveal re-crystallization based on classical XRPD testing. 
The different Dq values were pointing to multifractals as a better model than a simpler 
monofractal cluster distribution. A typical sigmoidal shape was evidenced with decreasing Dq 
along decreasing q values. 
Since the multifractal dimensions provide meaning to cluster distributions, they can 
prove helpful for understanding any early changes in ASD, but the physical interpretation of 
these clusters should be always in the context of the applied imaging method. The dimension 
D0 describes a space-filling capacity and values decreased in the early period of stability 
testing. This result was not easy to predict because there are different possible processes like 
drug migration to the surface that may increase the space-filling capacity. An increase could 
also come from drug that was previously too dispersed and low concentrated to be detected as 
a drug-rich domain so that local aggregation can lead to new clusters. While these are processes 
to increase D0, there are other effects that may potentially lead to lowered values of this 
capacity dimension. Some of the drug-rich domains of drug-polymer aggregates may locally 
become more concentrated in an overall phase separation or drug re-crystallization. The 
resulting more concentrated clusters would appear still white in the binary images so that 
overall space coverage could slightly diminish. 
The different cluster changes were apparently also leading on the average to a reduction 
in the information dimension D1. This dimension reflects the diversity of elements in the 
system. Moreover, D2 holds for a correlation dimension and the evidenced reduction was 
caused by the microstructural changes. Thinking of the transformation from amorphous 
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clusters to crystals there is of course nucleation as well as growth. Depending on which 
mechanism prevails, there would be different ways of how the correlation dimension changes. 
Regarding microstructural processes of phase separation, or crystal nucleation and growth, it 
is possible that different processes affect fractal dimensions in opposite directions, which could 
entail a loss of discrimination. The sensitivity to detect early physical instability by the 
multifractal approach is therefore certainly depending on the physical processes that occur as 
well as on the imaging technique used. 
The selected model systems showed some physical changes after four weeks with likely 
initial phase separation and occurrence of first crystals at the time of four weeks. Differences 
in the multifractal dimensions D0, D1, or D2 were indeed evidenced after one month compared 
to the initial analysis. Therefore, multifractals were capable of revealing microstructural 
changes caused by instability that were otherwise hard to identify from the original images of 
SEM-EDS and that were undetected by X-ray powder diffractograms (XRPD). It was in line 
with expectation that laser scanning confocal microscopy (LSM) and atomic force microscopy 
(AFM) were more sensitive methods than XRPD to capture changes so these reference methods 
were interesting to compare with the novel multifractal approach based on SEM-EDS imaging. 
2.2. Multifractal approach and influence of manufacturing 
technology  
ASDs can be processed by solvent based methods, heat-based methods, 
mechanochemical activation or a combination of these. The solvent based and heat based are 
the most commonly applied techniques. The first ones include techniques such as spray drying, 
solvent controlled precipitation, fluid bed, and supercritical fluid based technologies; the 
second kind of methods involve techniques as melt extrusion, melt granulation, and ultrasonic 
assisted compaction [45][46]. Depending on the selected manufacturing technique, an ASDs 
could have different behavior. For example, the type of interactions that may occur in solvent 
based methods can be different from that of heat-based methods, resulting in different 
microstructure and hence product performance. 
The XRPD analytical technique showed that all methods of preparation employed 
resulted in amorphous material, but XRPD did not provide further information about the 
amorphous phase. Thus, any presence of amorphous-amorphous phase separation should be 
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avoided as it can lead to drug crystallization. The analysis of differential scanning calorimetry 
(DSC) showed the presence of a single Tg indicating a homogeneous mixing, but it is known 
that a limitation of this method is detection of about < 30nm clusters to detect microstructural 
phase separation [47]. Complementary techniques are therefore needed to investigate such 
phase changes and imaging-based techniques provide here promising analytical options. The 
chemical imaging techniques are advantageous to detect clusters formation, even though the 
spatial resolution limits impact on the cluster’s determination. The clusters, which describe 
drug-rich regions of different types (as separate amorphous domains or small crystals) can be 
seen as mathematical objects with their characteristic fractal dimensions. Thus, fractal 
geometry could possibly be applied as a model of microstructural differences to obtain 
guidance on the selection of pharmaceutical manufacturing processes.  
The differences in the multifractal dimensions D0, D1, and D2 evidenced the differences 
in the microstructures that resulted from the selected manufacturing techniques. Such rather 
subtle differences would be otherwise hard to identify or even quantify from the original 
images of SEM-EDS. Table 1 shows the results of multifractal analysis in terms of the 
dimension with q values from zero to two. The difference between the values of Dq, that 
decrease with increasing q values, evidenced that the multifractals was a better model than the 
simpler monofractal cluster distribution, which would entail a constant Dq. 
Table 1  
Generalized fractal dimensions based on chemical imaging and conversion to binary pictures of 
indomethacine (IND) solid dispersions obtained with different manufacturing techniques. 
 
 Method Generalized fractal dimensions  
  D0 D1 D2 
IND/HPMCAS-LF 
Solvent 
coprecipitation 
1.86 ± 0.02 1.84 ± 0.01 1.79 ± 0.01 
(15:85) Solvent drying 1.75 ± 0.02 1.73 ± 0.02 1.68 ± 0.02 
 Melting 1.78 ± 0.01 1.77 ± 0.01 1.72 ± 0.02 
IND/HPMCAS-HF 
Solvent 
coprecipitation 
1.84 ± 0.01 1.82 ± 0.01 1.77 ± 0.01 
            (15:85) Solvent drying 1.75 ± 0.00 1.73 ± 0.00 1.70 ± 0.07 
 Melting 1.75 ± 0.01 1.74 ± 0.01 1.69 ± 0.02 
The dimension D0 describes the space-filling. High values can be indicative of drug 
migration to the surface that may increase the space-filling capacity, whereas lower values 
could be due to some concentrated clusters of drug-rich domains of drug-polymer aggregates 
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in an overall phase separation during the manufacturing process. The information dimension 
(D1) refers to the diversity of elements in the system, lower values suggest concentration of 
particles in a small domain. Finally, smaller values of D2 (correlation dimension) could indicate 
that the isolated clusters are prevailing versus the pore clusters, this could indicate initial 
amorphous-amorphous phase separation with drug-rich clusters that can cause future 
instabilities of amorphous systems.  
All Dq values were analyzed statistically. An analysis of variance (ANOVA) was 
conducted showing that the generalized fractal dimensions (D0, D1, and D2) were indeed 
statistically significant (p < 0.0001) to capture the microstructure variations regarding the 
different manufacturing techniques (see Fig. 1). The grade of HPMCAS was also significantly 
influencing D0, D1, and D2. A significant p value was also evidenced for the interaction between 
the method of ASDs production and the HPMCAS grade show. Fig. 1 shows a statistical means 
plot together with Tukey’s 95% HSD intervals. The significant of the technique applied was 
similar for all fractal dimensions. In figure 1 is shown for D0. 
 
HPMCAS grade 
 
HPMCAS grade 
Fig. 1. Statistical means plot of analysis of variance from IND/HPMCAS ASD formulation (15% wt% of IND) based on sums of squares 
ANOVA how D0 is affected by the manufacturing technique(a); the HPMCAS grade impact (b) and the interaction plot between the 
technique applied and the HPMCAS grade (c), the intervals of Tukey’s honestly significant difference (HSD, 95%) are shown.  
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The values obtained for the capacity dimension D0 were clearly below the Euclidian 
dimension (D=2) but still relatively high for all the manufacturing techniques. The D0 values 
for the solvent coprecipitation method for both polymer grades were considerably higher 
compared to the others, indicating that a more complex and irregular surface was obtained with 
this technique. This could be attributed to small crystals whose presence, was confirmed by the 
LSM analysis. The presence of crystals could be due to an incomplete conversion of the drug 
into the amorphous form. The values obtained for melt and solvent drying methods were 
similar, for the HPMCAS-HF the values were the same. With respect to D1, the values for 
solvent coprecipitation method were also appreciably higher compared to the other techniques. 
The melt and solvent evaporation techniques for HPMCAS-LF show a considerable difference 
being significantly higher for the melt method. On the other hand, for the HPMCAS-HF 
formulation the values were practically similar. Comparing the values of D2, the solvent 
evaporation method had rather small values. This could be due to the molecular mobility and 
the subsequent molecular re-orientation following solvent evaporation. 
Thinking of the microstructure and the manufacturing technique, the solvent 
evaporation method consists of an initial solubilization of drug and polymer in a common 
solvent (or a mixture of solvents) followed by solvent removal. This can give rise to the 
formation of non-covalent molecular interactions that are mainly responsible for the 
amorphization of drug. During the solvent coprecipitation technique, the use of organic 
solvents and antisolvent (water) represents already a medium with a comparatively high 
dielectric constant that can facilitate charge separation. Another difference to a classical solvent 
step such as spray drying is that the removal of solvent is comparatively slower. Such 
differences enable the formation of different molecular interactions, such as ionic, H bonding, 
dipole-dipole and van der Waals interactions. By contrast to any solvent-based method, the 
melting method is achieved by heating that enables a certain molecular mobility and a 
subsequent molecular re-orientation and formation of drug-polymer interactions.  In our study, 
increased temperatures were obtained by the ultrasonic energy applied during the compaction 
that provided heat and pressure. 
Regarding to the HPMCAS grade, the LF grade showed higher values for D0, D1, and 
D2 compared to the HF grade, which was attributed to a different substitution pattern between 
the grades. The HF grade has a relatively higher percentage of acetyl over succinoyl 
substitutions, which is opposite to the substitution pattern in the LF polymer grade. 
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 The likely differences in molecular led to a decrease in the value of D0, D1, and D2. In 
relation to the technique selected, this is true for solvent coprecipitation and fusion method, 
while no substantial decrease was observed for solvent evaporation.  
From these results, it can be stated that the given melting method was the most 
promising manufacturing technique for this studied system, IND-HPMCAS, based on the 
values obtained for multifractal approach and the implications these values may have on the 
microstructure, we can assume that for this combination the energy input was relevant for 
amorphization. Moreover, the solvent evaporation with the drug rich domains could induce 
future instability while the solvent coprecipitation even resulted in an incomplete 
amorphization. Therefore, a preferential order of techniques for this system is as follows: 
melting > solvent evaporation > solvent coprecipitation.    Regarding to the HPMCAS grade, 
the HF was deemed as the best grade for melting and solvent coprecipitation method. 
  
 
 
Chapter 3 
Benefits of fractal approaches in solid dosage forms 
development1 
 
Summary 
 
Pharmaceutical formulations are complex systems consisting of active pharmaceutical 
ingredient(s) and a number of excipients selected to provide the intended performance of the 
product. The understanding of material’s properties and technological processes is a 
requirement for building quality into pharmaceutical products. Such understanding is gained 
mostly from empirical correlations of material and process factors with product’s quality 
attributes. However, it seems also important to gain knowledge based on mechanistic 
considerations. Promising is here to study morphological and/or topological characteristics of 
particles and their aggregates. These geometric aspects must be taken into account to better 
understand how product attributes emerge from raw materials. Regulatory agencies worldwide 
are promoting innovative strategies that intend to create models based on scientific knowledge, 
such as physical or mathematical models, in order to design quality into a final product. This 
review deals with pharmaceutical applications of physical and mathematical models, focusing 
on percolation theory, fractal, and multifractal geometry. The use of these approaches improves 
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the understanding of different aspects in the development of solid dosage forms, for example, 
identifying critical drug and excipient concentrations. The aim is to link microstructure with 
macrostructure of pharmaceutical solid dosage forms as a strategy to enhance mechanistic 
understanding and to facilitate their development and manufacturing processes.  
3.1. Background 
The pharmaceutical industry constantly designs and develops new drug products, and 
improves their product development processes, with solid dosage forms as a preferred option, 
at least for small molecular drugs. The development from initial formulation design up to the 
final form and its translation to the market involves substantial labor time, cost, energy, and 
raw materials consumption [21][48]. Any reduction of the resource investment based on novel 
modelling approaches is expected to have a high industrial impact. 
The adequate selection of components and technology for the development of a formulation is 
required to meet high product quality expectations [21]. The quality is assured by 
understanding and controlling the relationship between formulation (drug and excipients 
attributes) and manufacturing variables (process parameters) [49]. These factors have a direct 
impact on the evolving microstructure [50], properties, and potential applications [21] of the 
dosage form. 
A range of imaging techniques such as scanning electron microscopy, transmission electron 
microscopy, profilometry, atomic force microscopy, Raman and near-infrared imaging are 
currently available to study outer surfaces and cross sections of solid particulate systems. The 
topography represents the microstructure of a sample, with a given spatial resolution and 
thereby provides a complex data set [51]–[53]. The data of surface topology can be complex 
as displayed in Fig. 2, which shows examples of uncoated tablets that were obtained by optical 
profilometry. Such data can be combined with chemical imaging so that spatial information is 
linked to the entire spectra. When imaging is two or three dimensional, large datasets are 
generated that can be substantially difficult to manage and interpret.  
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Models are needed to capture structural features and to generate correlations with 
relevant properties. Thus, the use of statistical tools helps to understand the relationship 
between the microstructure and the properties of the drug product in a science-based approach 
[54]. 
Descriptive mathematical model platforms can be used for interpretation of the results 
during the manufacturing process to predict the system properties but also for designing new 
robust formulations with suitable quality [48][55][56].  
This review focuses on fractal modelling approaches. It also describes the use of 
percolation theory to identify the critical points (e.g. drug or excipient concentrations) related 
to geometrical phase transitions of the system components, as a tool to define the design space. 
Moreover, further applications of fractal and multifractal approaches in pharmaceutical 
development of solid dosage forms are outlined. These tools provide an attractive and 
Fig. 2. Example of optical profilometry of uncoated tablets with (a) comparatively lower surface roughness and (b) tablet core 
exhibiting a rougher surface topology. Details are given in the text. 
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alternative path to gain insights into the characteristics of a formulation and could help with 
defining robust processes as needed by the pharmaceutical industry. 
 
3.2. Quality by Design (QbD)  
In the pharmaceutical industry, the companies are committed to improving the process 
control and product understanding. Quality by Design (QbD) was proposed by the Food and 
Drug Administration (FDA) and International Conference on Harmonization (ICH) as a 
systematic and innovate approach based on quality construction through the understanding of 
the relationship between the experimental factors and their impact on the quality attributes with 
minimum experimental runs offering a maximum return in terms of information [57]–[59].  
The QbD approach improves confidence in quality throughout the lifecycle of 
pharmaceutical products development and manufacturing, using risk management, and 
science-based manufacture principles. [49][59]. Several QbD tools such as product design, 
process design space, control space, operating space, and process analytical tools are frequently 
embedded in a risk-based approach [49]. 
During the development and regarding the manufacturing process, an appropriate 
control strategy should be developed. The study of parameters that impact the critical quality 
attributes provides the design space that together with an established control strategy are 
indispensable elements of contemporary product design and process development [59].  
A central position in the arsenal of QbD tools is taken by diverse analytical and process 
analytical methods, which have the potential to identify relevant properties as well as errors 
and deviations during the process to guaranty the quality of the products. Process analytics 
introduces a time domain to already complex data sets obtained from, for example, 
spectroscopic imaging. This underpins the aforementioned need for suitable mathematical or 
statistical modelling to cope with the flood of acquired data [60][61]. 
3.2.1 Design Space 
The design space is part of a control strategy, a combination and interaction of 
material’s attributes and/or process parameters that provides assurance of quality. Critical 
material attributes and process parameters are linked to critical quality attributes either by 
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statistical or mechanistic models. The material’s attributes and the manufacturing operating 
variables are defined in an acceptable range, including a quality assurance risk probability, and 
at the end, the product should provide similar quality specifications [49][58][62].  
The design space is based on the understanding of the product behavior and reduces the 
need for a larger amount of data [59]. To gain such understanding within restricted factor 
ranges, there are QbD tools, for example, design of experiment (DoE) that make use of linear 
to non-linear models [63]. The latter non-linear models are usually polynomials of second 
degree. However, at a critical point (i.e. critical concentrations of drug/excipient) there are 
highly non-linear effects that generally call for a more mechanistic modeling of the data and 
such a modeling tool is given by the theory of percolation. This approach has proven utility in 
the estimation of critical points of a formulation to predict the design space [56][64].  
 
3.2.2 Percolation Theory 
  In order to design a formulation with desired properties, it is crucial to know the basic 
properties and the spatial distribution of the employed substances. The components of a 
particulate systems (i.e. pellets, tablets) are expected to be randomly and often not 
homogenously distributed, which makes prediction of any mechanical properties difficult. If 
the degree of disorder is low, the behavior of the system can be predicted using renormalization 
tools; the opposite occurs if the medium is close to a percolation point, where disorder becomes 
very relevant [65]. Currently, percolation is a highly vivid and fascinating area of modern 
research that is reflecting many aspects of critical phenomena in an elegant way [66][67]. 
Percolation theory is a statistical physics approach able to describe a random 
distribution of disordered systems, based on their spatial correlations. It provides a framework 
to characterize geometrically how clusters of a components exhibit scale invariance, which can 
be also seen in experimental imaging[67]–[69]. Percolation is essentially a geometric approach 
to describe a geometric phase transition and it can be applied to model experimental parameters 
in the vicinity of a critical point, i.e. a percolation threshold.  
Percolation theory simultaneously describes a system’s cluster distribution and models’ 
critical properties to achieve physical insights. Percolation is grounded on a rigorous 
mathematical basis and has a very robust nature and stability in dealing with complex and 
dynamic models against small perturbations [34][67][68][70]. Despite its rather simple rules, 
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percolation theory has successfully been applied to describe a large variety of systems in 
natural, technical, and even social sciences [67]. 
The origins of percolation theory go back to Broadbent and Hamersley who proposed 
the basic concept and popularized the theory [67][71]. From a mathematical perspective, the 
concept of percolation is interesting due to the existence of a critical probability; on either side 
of the critical probability, the system behaves in different ways. One can imagine a lattice 
where sites are either occupied with a certain probability p or they are empty with the 
probability 1- p (i.e. site percolation). Instead of occupied sites, one can also think of setting 
bonds in a lattice with probability p (i.e. bond percolation). With increasing p, neighboring 
occupied sites (or bonds, respectively) form clusters that grow in size. A well-defined 
percolation threshold exists for which a sample- spanning cluster is formed for the first time. 
This incipient cluster exhibits a fractal nature [72].  
A physical correlation could exist on an atomic scale or it can be, for example on a scale 
of a porous particulate system where percolation occurs as connecting transport and diffusion 
once a percolation threshold of pores has been reached [34][73]. In pharmaceutical solid 
systems, a percolation threshold can be assigned to the minimum concentration of a given 
component at which it is expected to appear as sample- spanning cluster (or “infinite cluster” 
in the mathematical model) of this specific component, this means that above its critical mass 
volume (or mass) fraction, one component dominates the properties of the mixture 
[56][69][74]. In order to find this concentration, it is essential to have experimental systems 
(i.e. tablets, pellets, granulates, solid dispersions, extrudates, microspheres, etc.) with similar 
structures (i.e. porosity) but different component ratios [69][75]. Once a component reaches its 
percolation threshold (pc), the system undergoes a geometrical phase transition and this 
percolating component starts to extend over the whole system (Fig. 3). This influences the 
properties of the system in a non-linear way and it is possible to model different physical 
properties by power laws in the proximity of the percolation threshold, which is also called a 
critical point [56][67][71]. 
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The so-called correlation length characterizes the structure of the clusters below and 
above the percolation threshold [34][70]. The nature is only revealed on length scales smaller 
than the correlation length diverges in the percolation model to infinity at pc. Applied to 
physical systems this means that above the percolation threshold, a sample exhibits disorder 
throughout the entire sample. Thinking of pharmaceutical dosage forms, it is between the 
percolation thresholds of drug and excipient that both components form interpenetrating 
percolating clusters [74]. 
A physical (i.e. experimental) percolation threshold depends on the details of the 
system, such as drug solubility and particle size [76][77]. Below its percolation threshold, the 
clusters of the given component are finite and isolated. The percolation theory explains the 
evolution of the mechanical properties of compacts and mechanisms of tablet formation. This 
involves a volumetric ratio of components and is linked to external properties, i.e. tensile 
strength [54], water uptake [78], disintegration time [79] and intrinsic dissolution rate of tablets 
[75][80]. 
Fig. 3. Representation of a binary system where the dissolution efficacy is plotted against the fraction (% v/v) of A (blue) and 
B (green) particles, with an increasing concentration of A towards the percolation threshold (critical concentration). The five 
points (a-e) in the graph and the related snapshots of the system correspond to 2D representations of the microstructure. The 
point (a) show isolated A particles; point (b) exhibits the initial clusters formation of A particles; point (c) correspond to the 
percolation threshold of the A particles with a cluster from bottom to top and; (d) and (e) refer to systems where the component 
A is above its percolation threshold. Details are given in the text. 
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Apart from the aforementioned transport properties such as drug release from porous 
compacts, percolation theory has been also used to model mechanical properties of tablets as 
elastic modulus [81], compression behavior [82], and tensile strength [83][84]. Most of these 
experimental studies found rather broad ranges in which power laws of percolation theory were 
successfully applied. 
 
3. 3 Microstructure dynamics in a geometric view 
The formation and growth of clusters from individual particles or components is of high 
interest in complex heterogeneous systems [85]. The microstructural evaluation provides 
significant insight into the formulation performance. Controlling the microstructure of a 
pharmaceutical formulation is a key challenge and detailed features of the microstructure are 
even rarely known in formulation development. Accordingly, there is only an indirect control 
via the quality attributes of the final dosage form. It is known that the surface of many 
heterogeneous complex systems shows geometric irregularities together with defects. They are 
often self-similar upon variation in resolution. Such self-similarity characterizes a 
mathematical fractal. Unlike mathematical fractals, physical structures generally exhibit a 
fractal nature only in limited spatial or temporal ranges [27][86].  
Fractal is a geometric notion proposed by Mandelbrot and was further depth theorized 
by Evertsz and Mandelbrot [39] to describe in a fractal dimension (which is a non-integer 
number) the spatial and temporal self-similarity of objects, systems, and phenomena, based on 
an extension of the conventional Euclidean geometry [35][39]. Since fractals are ubiquitous in 
nature, the concept of fractals has been used in various scientific fields, including 
pharmaceutical sciences, to evaluate the geometry of a sample and mapping a structure in 
diverse quality parameters and to monitor chaotic systems performance (i.e. by time series 
analysis) [33]–[36]. 
Fractal geometry provides an understanding of the formation of the microstructure 
during the manufacturing process [30][87] that is hardly obtained by other conventional 
methods [88]. For solid pharmaceutical dosage forms, self-similarity and hence the irregularity 
degree of an object or feature can be represented by a non-integer fractal dimensional value 
(Df). The Df values can be derived, for example, from surface imaging techniques to 
characterize the geometry, surface roughness, particles shape, or size as well as the degree of 
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spatial complexity [32]. Smooth surfaces, for example have a low fractal dimension, whereas 
highly textured surfaces have a high fractal dimension [30]. Apart from surface morphology, 
fractal analysis can also help to study solvent-mediated phase changes of pharmaceuticals. 
Thus, hydrate formation on the surface of a solid in an aqueous medium has also been analyzed 
using binary images. In the course of hydrate conversion, clusters were forming and resulted 
finally in a Df of 1.85 that was not only interesting to describe the structure but also to reveal 
the underlying mechanism of hydrate nucleation and growth by diffusion [89].  
Simple fractals can be generalized to a more versatile multifractal spectrum, which can 
be used to describe subtle geometrical features of a fractal object, which cannot be fully 
described by a single fractal dimension [36][38]. This multifractality is accessible through 
experiments or simulations via the moments of the distribution (Dq). Some of these multifractal 
moments are corresponding to quantities that have a particularly prominent role in percolation 
theory [66]. 
Important to note is that fractals provide a model framework that includes percolation 
theory. There are further applications to solid dosage forms for example regarding drug 
dissolution or to describe morphological or topological features of a solid formulation by 
mapping of the structure including information related to shape, mechanical, and further 
material properties [27][30][90][91]. Fractal physics (and in particular as described by 
percolation theory) demonstrates that a small perturbation of microstructural details (in a 
critical range) can lead to substantial macroscopic changes of the system properties [86].  
The understanding provided by fractal geometry is based on the paths of microstructural 
change, and this is governed by the spatial distribution of topological events. A system 
component can, on the level of the microstructure be uniformly distributed in space or it can 
be aggregated into clusters [67][92]. Thus, clusters with diverse shapes and sizes spread in 
random directions and lead to geometrically irregular bulk structures and surfaces [93]. The 
initial stage of cluster formation is known as nucleation and is followed by densification and 
smoothing of the initial mass fractal structures. At this point, the system forms self-similar 
structures over wide spatial ranges. Physical porous objects typically exhibit pores (or solid 
particle structures) of almost all sizes, which can be evaluated by the box-counting method to 
quantify porous channels and surface structure [37] and be described either by a single fractal 
or by multifractal dimensions (Fig. 4) [68][94]. 
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The continuation of the process and the forward of the cluster aggregation is related to 
the type of particles and the input energy in a system. Such aggregation can lead to self-similar 
clusters and upon further densification, clusters start to interpenetrate, which may follow the 
principles of percolation theory [95]. Compared to a random distribution, an aggregated system 
has more “free space” and hence the diffusion kinetics of such a system may be different [70], 
[93].  
There is practical relevance for the case where components of a system are above the 
percolation threshold and thereby form independent system spanning clusters that are 
interpenetrating each other [70][93]. The interpenetrating process of clusters influences the 
topological properties of the whole system [96]. Below the percolation threshold, the structure 
represents a complex system of finite clusters from which a (fractal) percolating cluster 
emerges. Further, above a percolation threshold, densification of interpenetrating clusters leads 
to smaller and smaller length scales (i.e. correlation lengths) below which heterogeneity is 
observed. Upon such densification, the percolating cluster ceases to be fractal, becomes 
homogeneous and acquires dimensionality of the embedding space on scales that are bigger 
than the correlation length. [73][96]. Thus, combined insights from fractal geometry (and 
percolation theory in particular) provide a geometry-based framework to better understand 
physical systems that can be idealized based on cluster aggregation [92][97]. Thinking of 
tablets, clusters of a mathematical model can hold for different physical substructures of the 
Fig. 4. (a) Example of typical two-dimensional EDS binary pictures microstructure seen by EDS of a binary mixture of 
Felodipine and HPMCAS-LF at initial time (t0). (b) Microstructure evaluation of binary mixture after 4 weeks at 40◦C (tf) 
showing drug-rich phase (white domains). (c) Generalized dimension Dq spectrum over the [0;2] moment q range for t0 and 
tf. Figure adapted from (Abreu-Villela et al., 2018). 
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compact such as, for example, pores, or primary particles, or even a mesoscale of an aggregated 
component in mixtures depending on which system and tablet property is considered. 
Hence the science of solid formulations is a complex area in pharmaceutical 
technology. Unlike simple solutions, a molecular understanding and modelling is currently not 
given to an extent that it can be ‘translated’ into laws for particles and their compacted tablets 
[98]. Scaling law models provide an opportunity to connect the microscale to the macroscale 
[69]. Such scaling laws are part of fractal physics as well as percolation theory and provide at 
least some mechanistic description. This means, for example, that a power law of percolation 
may come with a theoretically known percolation threshold and exponent, but the 
proportionality constant is not predictable by theory. 
 
3.4. QbD perspective: contributions of percolation theory 
and fractal geometry  
The percolation theory and fractal geometry approaches are promising to describe solid 
formulations and especially mixtures with different components such as drug and excipients. 
Understanding of formulations is important to identify for example critical points in the design 
of formulations and in a process for effective development. Fig. 5 illustrates a path for 
implementation of QbD approach.  
Percolation thresholds should be known in order to define the Design space of a 
formulation that exhibits a critical range of a quality attributes. These thresholds hold for 
critical volume of mass ratios and in their vicinity, small changes generally have pronounced 
effects on either process or final quality attributes. Its case of tablets this could mean effects 
on, for example lamination, capping, and changes in tensile strength of the compacts. 
Interesting is the view that data-mining acquired from percolation theory could be a useful tool 
to predict the manufacturing route sensitivity [99] providing a science-based approach for the 
estimation of the Design space [56]. One example can be found in the field of sustained release 
matrix tablets for which the knowledge of the critical concentrations of drug and matrix former 
polymer is vital to obtain formulations with a robust sustained release behavior [56]. Critical 
concentrations of a tablet component have also shown to be relevant for designing binary or 
multicomponent pharmaceutical tablets of to achieve sufficient mechanical strength [100]. 
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Interesting is further another example of binary drug-excipient mixtures for which a critical 
concentration of drug was identified, above which powder mixtures showed highly erratic flow 
[101]. The same study further showed that such high drug concentrations close and above the 
critical point were leading to a sharp increase in dosing weight variation of the final dosage 
form (i.e. capsule). [102] investigated powder blend behavior and segregation tendency by 
considering percolation threshold. Another interesting field is application of percolation theory 
in the field of pharmaceutical colloids. For example, phase transitions of liposomes and the 
medium properties were evaluated in the framework of  percolation threshold [103]. There are 
many possible applications of fractals in the field of pharmaceutical nano delivery systems. 
This is relevant not only for nano systems as final dosage form but also regarding colloids that 
emerge after oral administration of solid dosage forms as for example solid dispersions. Such 
nano systems could also serve as intermediate products for a solid dosage form development 
[28][35]. The fractal approach was also been proposed as a complementary tool for evaluation 
of the morphological characteristics of nanosimilar products [104]. Furthermore, fractals 
proved to be helpful to evaluate the stability of liposomal systems [105]. These different studies 
of pharmaceutical nano systems suggest that fractal aspects need to be studied to design quality 
into colloidal drug delivery systems.  
 
Interactions of colloidal clusters play also a role in the field of nanocomposites. The 
distribution of silica nanoparticles in nanocomposites and its impact on the mechanical 
Fig. 5. Main steps of QbD approach for design space and process understanding from formulation (percolation) 
and process (fractal & multifractal) characterization and their impact in quality throughout the development and 
manufacturing process of pharmaceutical products 
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properties of the system was also evaluated based on the concept of percolation [106][107]. 
Such applications in pharmaceutically relevant material sciences are especially promising. This 
may not only target material properties for drug delivery systems directly but is also relevant 
for designing membranes that are used ubiquitously in the pharmaceutical sciences. For 
example, the influence of the particle diameter on the percolation threshold in a membrane 
formed by spherical nanoparticles has been studied using a computer simulation program 
[108]. These results are in agreement with the experimentally found by our research group 
more than two decades ago [109][110] showing a decrease in the percolation threshold as the 
particle diameter increases. 
Other more recent pharmaceutical work on amorphous solid dispersions revealed that 
excipient and drug clusters are better described by multifractal formalism than by a single 
fractal dimension [36][111]. The findings based on imaging techniques were shown to impact 
quality attributes such as mechanical strength and physical stability of the analyzed solid 
dispersions [53][112]. 
In conclusion, the rough topography or complex pores structure of solid dosage forms 
is not directly predicted by any model with a Gaussian distribution. However, fractal geometry, 
the multifractal approach and the models based on percolation theory have been proposed to 
describe the statistical properties of such surfaces and bulk morphologies. Percolation theory 
has been successfully applied for identification of critical concentrations of formulations that 
impact on critical process and quality attributes of the final dosage form.  
The given examples and the theoretical considerations demonstrate how promising the 
concepts of fractal geometry and percolation theory are to address the QbD philosophy to bring 
important benefit for optimization of formulations. Particular advantages of this approach are 
the sound mechanistic basis of taking the microstructure into account that is mostly a “black 
box” in classical DoE approaches. Such statistical designs are, on the other hand, very 
economical in terms of experimental investment, but it seems best to combine purely 
correlative knowledge based on for example DoE with more mechanistic approaches as 
presented in this review. 
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Electron microscopy/energy dispersive X-ray 
spectroscopy of drug distribution in solid dispersions 
and interpretation by multifractal geometry2 
  
Summary  
Much contemporary research of poorly water-soluble drugs focuses on amorphous solid 
dispersions (SDs) for oral drug delivery. Recently, a multifractal formalism has been 
introduced to describe the distribution of an inorganic carrier in SDs. The present work 
attempts to directly image model drugs by means of scanning electron microscopy and energy 
dispersive X-ray spectroscopy. The compounds amlodipine, felodipine, glyburide, and 
indomethacin, which include halogens to enable sufficient scattering in energy dispersive X-
ray spectroscopy, were employed to prepare SDs with hydroxypropyl methylcellulose acetate 
succinate (HPMCAS) by using a microwave method. Following chemical imaging, it was 
demonstrated that drug distribution was best described by multifractals, which was clearly 
superior to a monofractal assumption. The obtained fractal dimensions were influenced by drug 
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loading and it was possible to detect microstructural changes upon addition of the plasticizer 
urea. Accordingly, the multifractal approach bears much potential to better explore the 
analytical results of chemical formulation imaging. Insights can be gained from the 
microstructural organization of SDs, which is interesting to further study formulation and 
process factors as well as physical stability. 
4.1. Introduction 
Solid dispersions (SDs) provide an important formulation approach to improve 
dissolution and apparent solubility of an active pharmaceutical ingredient (API) that is poorly 
water-soluble [4][6][47]. However, SDs also come with some technical challenges such as 
thermodynamic instability. An increased understanding of drug properties and 
physicochemical interactions with matrix components has been achieved in recent years, which 
is lever-aging such development risks [1][10][48][49]. Among the different analytical tools, 
imaging methods have become increasingly important nowadays. A potential phase separation 
has been studied, for example, by cross-polarized imaging, vibrational spectroscopic imaging 
or atomic force microscopy (AFM) [17][50][51]. Depending on the method, such imaging of 
a phase separation may provide a clear visual result. However, direct insight from looking at 
obtained images is unfortunately often not achieved. Imaging may just show a complex cluster 
structure that is difficult to compare and interpret at given length scales. Few studies have, for 
example, investigated microstructures by means of AFM at a size range of nanometers [118]. 
It is in this respect indifferent, whether an obtained cluster structure was calculated by a 
chemometric method or if a cluster distribution was obtained directly from a given imaging 
method. 
A lack of direct interpretation by the naked eye can be unsatisfying. The approach of a 
simple cluster statistics by determining their size and number can be rather tedious, especially 
in absence of an automated computer program. Moreover, a comparison of mean cluster sizes 
may offer only limited sample differentiation [20]. There is an obvious need of advanced data 
processing once images are obtained to extract relevant structural information from solid 
dosage forms. Such data processing can be geared towards for example homogeneity 
[19][20][53]. However, it may be even more attractive to apply a mathematical model for 
heterogeneous physical structures such as fractals [120]. Even though there are many 
applications of fractals in pharmaceutics [35], there are fewer reports in which fractals are 
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applied to dynamic imaging of dosage forms [89]. Thus, fractals appear to be rather 
underexploited for imaging of pharmaceutical dosage forms compared to, for example, medical 
imaging [121]. The fractal approach offers a physical model, which enables more than just 
sample comparison as it bears potential to gain mechanistic insights into how a microstructure 
has been generated. Recently, multifractal formalism was introduced to pharmaceutics to 
analyze data from electron microscopy and energy dispersive X-ray spectroscopy [36][57]. 
This pioneer work of microstructural analysis focused on inorganic carrier distribution in 
pharmaceutical extrudates and consequences on mechanical hardness. 
The present work attempts for the first time to employ multi-fractals for analysis of the 
drug distribution in SDs. Thus, different APIs were selected which include halogens to enable 
sufficient scattering in energy dispersive X-ray spectroscopy. The model polymer 
hydroxypropyl methylcellulose acetate succinate of grade “LF” (HPMCAS-LF) was used as a 
carrier matrix. This grade has relatively higher succinoyl substitutions (14–18%) as compared 
the others grades, i.e. MF (10–14%), and HF (4–8%) [122], which affects hydrophilicity of a 
solid dispersion [123]. There was a specific aim to study effects of the formulation on the 
obtained fractal dimensions. Herein, drug load was of interest but also the addition of urea 
because this excipient has shown promise for reducing the manufacture temperature as well as 
to improve drug release from SDs [124]. 
4.2. Materials and methods 
4.2.1. Materials 
HPMCAS-LF (Shin-Etsu AQOAT®) was kindly donated by Shin-Etsu Chemical Co. Ltd. 
(Tokyo, Japan). Amlodipine (AML) and glyburide (GLY) were purchased from Molekula Ltd. 
(Newcastle Upon Tyne, UK), felodipine (FEL) and indomethacine (IND) from Kemprotec Ltd. 
(Smailthorn, Cumbria, UK), whereas urea was purchased from Sigma-Aldrich (St. Louis, 
Missouri, USA). Physicochemical properties of the AML, FEL, GLY and IND are showed in 
Table 2.  
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Table 2  
Physicochemical API properties. 
Compound 
Molecular weight 
(g/mol)a 
Melting Temperature 
(◦C)b 
logPa pKaa Water solubility 
(mg/mL) at 25 ◦ Ca 
Total solubility parameter 
(MPa)1/2 c 
Amlodipine 408.8 140.5 3 9.45 0.0074 22.5 
Felodipine 384.3 144 3.86 5.39 0.0072 23.0 
Glyburide 494 173.5 4.7 4.32 0.0021 24.7 
Indomethacine 356.7 161.5 4.27 4.5 0.0024 23.5 
a Molecular weight, partition coefficient logP, dissociation constant pKa and predicted water solubility are taken from the 
DrugBank database (https://www.drugbank.ca/). 
b Melting temperature values taken as the average maximum temperature of melting endotherm for three samples.  
c Hansen Solubility parameter estimated by the software Molecular Modeling Pro V.6.2.6 (Norgwyn Montgomery 
Software Inc., North Wales, PA). 
4.2.2. Methods 
4.2.2.1. Preparation of physical mixtures and solid dispersions by microwave heating 
The present work was making use of a microwave irradiation (MW) preparation method 
that was similar to what has been reported before [124]. Defined amounts of the different 
components (i.e. 1 g) were mixed at room temperature at various weight ratios (Table 3), water 
was added, and the mixtures were stirred at 700 rpm for 15 min. 
The obtained homogeneous suspensions were transferred into a vial containing a 
magnetic stir bar. SDs were produced by using microwave assistance in a Biotage Initiator 
system (Biotage, LLC; Charlotte, NC, USA) operated and controlled by the software. The 
samples were heated to 120◦ C with a power of 75 W during 10 min and later cooled to room 
temperature before being dried and freeze/milled (Spex Sample Preparation; Metuchen, New 
Jersey, USA). Following milling, no visual changes were observed except for an intended size 
reduction and particle uniformity. Subsequently, samples were stored in a desiccator until 
further investigations. 
4.2.2.2. X-ray powder diffraction 
X-ray powder diffractograms (XRPD) were determined for physical mixtures (PM) as 
well as MW formulations. A D2 Phaser diffractometer (Bruker AXS GmbH, Karlsruhe, 
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Germany) was employed that was equipped with a Co–2 K KFL diffraction tube configured 
and a 1D- Lynxeye detector and with a Fe filter. The applied voltage and current were 30 kV 
and 10 mA, respectively. Diffraction patterns were obtained using a step width of 0.02◦ C with 
a detector resolution in 2 between 6 and 40◦ and a scan speed of 2s/step at room temperature. 
Data interpretation was per-formed by using the EVA program (Bruker AXS GmbH, 
Karlsruhe, Germany). 
4.2.2.3. Preparation of compacts 
Powders of MW formulations were compressed with a tablet press to facilitate a smooth 
and flat sample surface for subsequent chemical imaging. 100 mg of SD and 7 mm flat faced 
punch was used as tooling for a manual compaction using a hydraulic XP1 press (Korsch AG, 
Berlin, Germany). 
4.2.2.4. Scanning electron microscopy and energy-dispersive X-ray spectroscopy 
The samples were placed on double-side adhesive carbon tabs and the surface of the 
compacts was coated with gold under argon vacuum with a Sputter Coater SC7620 (Quorum 
Technologies Ltd., Kent, UK), which was observed with a Scanning electron microscopy 
(SEM) TM3030 PLUS (Hitachi High-Technologies Corporation, Tokyo, Japan). A voltage of 
15 kV and 150× magnification was used. Energy-dispersive X-ray spectroscopy (EDS) 
analysis was based on a Quantax 70 system software (Bruker Nano GmbH, Berlin, Germany) 
consisting of an X Flash Min SVE signal processing unit, a scan generator and Megalink 
interface together with an X Flash silicon drift detector 410/30H (Bruker Nano GmbH, Berlin, 
Germany). Samples were scanned during 5 min to map the distribution of APIs that contain 
chloride (Cl) atoms for comparatively higher X-ray scattering intensity. 
4.2.2.5. Image processing and multifractal analysis 
Once the images of the studied object were captured, they were processed using Adobe 
Photoshop Creative cloud software (Adobe Systems, San Jose, California, USA). Each picture 
was converted to binary images of 1024 × 768 pixels for which black was set as background. 
A predetermined image size avoids artifacts, which may occur when boxes do not entirely 
cover the image at the borders. The Image J software (National Institutes of Health, Bethesda, 
Chapter 4 
 
40 
Maryland, USA) plugin image analysis tool FracLac was employed to perform the box 
counting multifractal analysis. The number of grid orientations, the maximum box size as% of 
pixels, and the moment q range were set to 4, 60, and [-5; 5], respectively. A power series of 
box sizes was selected with 2, 4, 16, 64 and 256 pixels. Three compacts of each formulation 
were analyzed. 
A Box counting method to cover a 2-D image was used for calculation of fractal 
dimensions. Thus, successive grids of sizes ε were used for this purpose. The number N of 
boxes containing at least one pixel of the observed object was recorded and the procedure was 
repeated with different grids to compute fractal dimensions [54][56][61]. In a monofractal 
system, the object measured is assumed to have a structure, which is repeated over different 
spatial scales. However, complex structures may not entirely be described by monofractal 
analysis. In multifractal analysis sets can also be characterized trough the scaling of qth order 
moments of Pi distribution. The box counting method determines the partition function X (q, 
ε), which can be considered as the probability to find the object in the ith box for different 
moments q varying in the [–∞; +∞] interval. The generalized dimensions are obtained as the 
slope of the portion function over box size, both taken as logarithms (Equation reference 
[36][56]). This method is knowns as the method of moments, Dq. 
Dq can be viewed as the “deformation parameter” of variability degrees and q extracts 
different features of the distribution. Particularly interesting are D0, D1 and D2, where D0 refers 
to the “capacity” dimension that describes how a multifractal system covers the observed 
domain. The parameter D1 is called a dimension of Shannon entropy that characterizes the 
degree of disorder in a distribution. Finally, D2 hold for the “correlation” dimension, which 
indicates a degree of clustering. If the values for D0, D1, and D2 are for example rather high, 
this would suggest a high degree of space coverage, high disorder, and low clustering level, 
respectively [126]. In case of monofractal self-similarity, D0 = D1 = D2, whereas different 
values D2 ≤ D1 ≤ D0 indicate a multifractal system [127]. 
4.2.2.6. Statistical analysis 
STATGRAPHICS Centurion XVI ed. Professional (V. 16.1.15) from Statpoint 
Technologies Inc. (Warranton, Virginia, USA) was used to evaluate analysis of the variance 
(ANOVA). Tukey’s honest significant difference test was used for means comparison of 
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generalized multifractal dimensions D0, D1, and D2. For all the statistical tests, a p-value <0.05 
was considered significant. 
4.3. Results and discussion 
4.3.1. Preparation of solid dispersions and X-ray diffraction 
SDs can be prepared by a solvent method or based on application of heat, as it is the case 
for hot-melt extrusion (HME) or a MW method. The latter method is attractive due to its 
simplicity but not all polymers can be processed in this way and lack of shear forces compared 
to HME may require elevated manufacturing temperatures [62][63]. This is one of the reasons 
why urea is an interesting excipient for MW because it bears potential to reduce manufacturing 
temperature [124]. However, all formulations of the present study (Table 3) were processed 
without any complications. XRPD (Fig. 6) of the physical mixture (PM) showed distinct visible 
peaks that were pointing to drug that remained crystalline as expected. By contrast, all the 
formulation produced in the microwave showed only a halo, so the absence of peaks indicated 
the successful conversion of the APIs to their amorphous forms in the SDs. The macroscopic 
appearance of the different SDs of IND was transparent and suggested the likely formation of 
glass solutions. By contrast, the other amorphous drug formulations exhibited different degrees 
of macroscopic turbidity that together with the XRPD results indicated the formation of glass 
suspensions [10]. 
Table 3  
Composition of the different solid dispersions. 
 
Drug 
%(w/w) 
HPMCAS-LF 
%(w/w) 
Urea 
%(w/w) 
Formulation 
AML 5 95  AML5 
AML 7.5 92.5  AML7.5 
AML 10 90  AML10 
AML 10 85 5 AML10U 
FEL 5 95  FEL5 
FEL 7.5 92.5  FEL7.5 
FEL 10 90  FEL10 
FEL 10 85 5 FEL10U 
GLY 5 95  GLY5 
GLY 7.5 92.5  GLY7.5 
GLY 10 90  GLY10 
GLY 10 85 5 GLY10U 
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IND 5 95  IND5 
IND 7.5 92.5  IND7.5 
IND 10 90  IND10 
IND 10 85 5 IND10U 
 
4.3.2. Compact surface mapping by energy-dispersive X-ray spectroscopy 
It is known from the literature that SEM-EDS is the mostly used technique for 
representation of elemental composition from micro-scale surface, with a detection limit of 
approximately 0.1% [62][63]. The overall spatial resolution of the method is limited by the 
focused beam and the scattering of elastic or inelastic electrons. If the beam is finely focused, 
it provides a high spatial resolution even for mapping bulk species in the range of 10 keV to 
30 keV [128]. Since SEM-EDS application focus on elemental specific localization and 
distribution on the compact surface [129], we selected model drugs that contain Cl atoms as 
they are generally well detected by SEM-EDS given that their elevated atomic number 
facilitates relatively higher X-ray scattering intensity in organic molecules. Representative 
SEM and the corresponding EDS-2D binary pictures of drug formulations are shown in Fig. 7. 
The light pixels of the latter 2D representations were specific for detected Cl atoms that were 
Fig. 6. Power X-ray diffractograms of 90/10% (w/w) HPMCAS-LF/API PM, 85/10/5% (w/w) HPMCAS-LF/API/U PM, 
90/10% (w/w) HPMCAS-LF/API MW, 85/10/5% (w/w) HPMCAS-LF/API/U MW, where the APIs are AML, FEL, 
GLY, IND. Details are explained in the text. 
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only present in the drug molecules. From those micrographs, it becomes apparent that the drugs 
were not homogeneously dispersed throughout the samples. At first sight, SEM-EDS images 
suggest a complex structure of clusters, but the absence of comparatively large domain 
formation shows that there was no pronounced phase separation given in the studied SDs. 
 
4.3.3. Multifractal analysis 
4.3.3.1. Image analysis 
Inspecting the Cl distribution on the 2D images by the naked eye can barely provide 
insights beyond the finding of an absent larger-scale phase separation. For a more refined 
cluster analysis, this work introduced the multifractal approach to study drug distribution. This 
was employed as a tool to quantify the complexity and spatial heterogeneity of compound in 
SDs. It is of course important to recall that the 2D representations were images of a 3D 
topography [130] but the samples were comparatively flat, and the scaling approach of any 
fractal algorithm should enable a rather versatile use for drug distribution analysis. 
4.3.3.2. Multifractal analysis of binary system 
Fig. 7. SEM (a, b, c, d) and corresponding EDS 2-D binary pictures (e, f, g, h) of Cl distribution in tablets containing 90/10% (w/w) 
of HPMCAS-LF/API, where the APIs are AML (a, e), FEL (b, f), GLY (c, g) and IND (d, h). 
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The multifractal approach as a cluster analysis was used to study SDs. It is known that 
drug can be incorporated differently in a matrix dependent on the type of amorphous 
formulation [6]. However, the categories in the literature such as glass solutions or glass 
suspensions are umbrella terms for systems that can be quite variable in their microstructure. 
Drug clusters can exhibit very different space coverage and the degree of disorder and level of 
clustering can show differences. In line with previous work on excipient distribution, a 
particular interest was therefore in the fractal dimensions D0, D1, and D2 [112]. These obtained 
numbers are generally sufficient to thoroughly characterize a cluster structure. Space coverage 
(“capacity dimension”) in a given domain is obtained by D0, whereas D1 (“information 
dimension”) holds for a degree of disorder, and finally the correlation dimension D2 
characterizes the degree of clustering (“correlation dimension”). 
A first interest was to see whether results would be different among the model drugs 
studied (Table 2). AML and FEL have basic moieties, whereas GLY and IND are acidic drugs. 
All model compounds exhibit poor water solubility, they were selected in confined ranges of 
lipophilicity and solubility parameter, and an initial screening test revealed the suitability of 
these model com-pounds to produce SDs with HPMCAS-LF. As a result of the multifractal 
analysis, the evolution Dq versus q for the formulations AML10, FEL10, GLY10, and IND10 
(in the range of moment q [-5; 5]) displayed sigma-shaped curves and Dq decreased with higher 
values of q. This shows that the multifractal approach does not introduce any unnecessary 
complication because the simpler monofractal model would be clearly inadequate, as it would 
assume a single constant fractal dimension along different values of q. It was interesting to 
investigate specific influences of given compounds on the multifractal dimensions. A more 
detailed view on D0, D1, and D2 is given in Fig. 8 and the upper panels (a)-(d) to compare 
different drug loadings. Results suggest some effect of the compound as well as of its 
concentration on the microstructural features of the SDs. Fig. 8 (a-d) indicates for AML10, 
FEL10, GLY10, IND10 that rising drug concentrations increase the different dimensions 
thereby indicating a higher space coverage (D0), higher dimension of disorder (D1) and higher 
correlation dimension (D2), which in turn suggests a lower degree of clustering. Current results 
bear interesting qualitative similarity with D0, D1, and D2 values that were reported as 
multifractal results for the distribution of an inorganic carrier in hot melt extrudates [36]. 
The observed effect of compound and drug loading were also statistically analyzed at a 
reference drug load of 10% (w/w). A two-way ANOVA conducted and supported the view of 
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a significant API effect on D0 (p = 0.0012) as well as a clear effect of drug load on the same 
dimension (p < 0.0001). Fig. 9 allows comparing the Tukey’s 95% highest significant 
differences for the different drugs or concentrations, respectively. A most pronounced 
difference for the API type was between AML-FEL and FEL-IND. An interpretation of this 
result is that molecular interactions of the compound with HPMCAS would define a particular 
microstructure of how drug clusters form in a SDs. 
Fig. 8. Generalized dimension Dq spectrum over the [0;2] moment q range for solid dispersions. The upper four 
panels (a)-(d) show drug concentration effects, while the lower panels (e)-(h) display effects of added urea (5% 
w/w) at a constant drug load (10% w/w). Details are explained in the text: AML5, AML7.5, AML10 (a); FEL5, 
FEL7.5, FEL10 (b); GLY5, GLY7.5, GLY10 (c); IND5, IND7.5, IND10 (d); AML10, AML10U (e); FEL10, 
FEL10U (f); GLY10, GLY10U (g); IND10, IND10U (h). 
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The dimension D1, and D2 were also studied in a two-way ANOVA of the same factors 
and results were quite comparable with respect to obtained p-values. These values remained 
practically the same for D1 as for D0 (rounded for four digits after the comma). Regarding D2, 
the effect of drug yielded a very similar p-value of 0.0014 for API type and again p < 0.0001 
for drug loading. The qualitative differences among compounds were comparable with respect 
to D0, D1 and D2. Thus, APIs were obviously affecting in their particular way the microstructure 
of the SDs even though the trends in changes of fractal dimensions were quite comparable. 
The topic of drug distribution in amorphous dispersions has been also approached by 
molecular dynamics simulations (MD) that showed a non-uniform distribution of drug in a 
polymeric matrix [131]. MD simulations can not only analyze the drug aggregation and 
formation of supramolecular structures in a polymeric melt but also upon aqueous dispersion 
[132]. While such atomistic simulations are beneficial to learn about molecular drug-excipient 
interaction motifs, it is currently hardly possible to get quantitative information on the cluster 
structure of formulation components because this would require a substantial increase in 
computation resources. In the future, MD simulation results might be compared with findings 
of cluster analysis as studied by the multifractal approach. 
Fig. 9. Statistical means plot based on a two factor ANOVA how D0 is affected by the drug (10% w/w) in solid 
dispersion (a); and D0 as influenced by drug concentration (b). Tukey’s highest significant differences (95%) are 
shown. 
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Interesting for an alternative technique of drug distribution analysis is a fluorescence 
study that was based on fluorescence resonance energy transfer (FRET) [133]. This technique 
had the disadvantage that only the distribution of fluorescence probe molecules could be 
studied but an interesting finding was the cluster nature of how model compounds were 
spatially distributed in the matrix. We found in the current work also a cluster structure of drug 
in the solid dispersions of IND, which appeared rather as glass solutions by their macroscopic 
appearance. The current analysis is of course a snapshot in time, so it is possible that initial 
nuclei of an amorphous-amorphous phase separation have already formed but were too small 
to be seen macroscopically. Further studies of such time-related changes [10] are of interest 
but would go beyond the scope of the current work. 
The multifractal approach provides major benefits for chemical imaging of SDs because 
effects of formulation parameters can be detected in the microstructure. This was in line with 
prior work that focused on the distribution of an excipient in SDs [89]. Any simple assumption 
of a homogenous drug distribution in SDs or a distribution that can be described as a 
monofractal system falls short in light of the present results. A proper understanding of such 
heterogeneous drug distributions obviously requires studying different length scales. 
4.3.3.3. Multifractal analysis of ternary system 
To extend the multifractal approach to more complex systems, ternary mixtures with a 
concentration of 5%w/w urea were analyzed. The latter additive is of interest from a 
formulators perspective regarding a potential reduction of manufacturing temperature and it 
has shown some promise to enhance drug release [124]. For the present work, a primary 
objective was to see how the presence or urea would perturb drug distribution in the SD and 
how these microstructural effects would be reflected in terms of the fractal dimensions. 
The more complex ternary systems were viewed as simple mixtures of API with a matrix 
of excipients. For chemical imaging, this approach results in “pseudo-binary images” [134] 
that depict drug in a matrix of additives. Fig. 8 (e)-(h) indicated multifractal analysis of API 
distribution indicating a lower generalized dimension on formulation with urea, corresponding 
to a lower space coverage (D0), lower heterogeneity (D1) and higher clustering level (D2). In 
contrast to all other APIs, SDs of IND and polymer had lower values of D0, D1 and D2 than 
IND formulations with added urea. 
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An ANOVA of the formulations with 5% (w/w) urea and their corresponding reference 
systems without urea supported the view of a significant drug effect on, for example, D0 (p = 
0.0212) and a significant effect of adding urea (p = 0.0183). These effects were also found to 
be significant regarding D1 (p = 0.0325 for the effect of drug type and p = 0.0261 for that of 
urea). The corresponding ANOVA for D2 has revealed a borderline effect for the drug (p = 
0.0512), while the significance level was again reached for the urea effect (p = 0.0336). 
From a mechanistic perspective, urea could have different effects. Owing to its particular 
structure, urea has the ability to interfere with hydrogen bonding. An influence of urea on 
hydrogen bonding patterns in solid dispersions is therefore interesting but would require 
additional spectroscopic studies for clarification. There could be also general effects of urea on 
the cluster structure so that a simple dilution of polymer in the pseudo-binary images could 
have played a role in the observed fractal dimensions of the ternary mixtures. 
4.4. Conclusions 
SEM-EDS application on the surface of solid dispersion samples showed a suitable 
detection of the different model drugs that contained Cl. This multifractal analysis of SEM-
EDS images proved to be reproducible and robust. It provided the means to assign numbers to 
a heterogeneous structure as observed from chemical imaging. The present work attempted for 
the first time a multifractal analysis of drug distribution in SDs and proved the superiority 
compared to any model description that is based on a single fractal dimension. The analysis 
allowed detecting effects of different drug types and their concentration on the microstructure. 
Notable was that the promising additive urea showed clear effects on the different fractal 
dimensions. Chemical imaging together with the multifractal approach bears much promise 
from a theoretical as well as practical perspective. Complex cluster structures can be analyzed, 
and structural insights can be gained that may help to better under-stand the performance of a 
SD or of another type of pharmaceutical dosage form. Future work could study time-effects 
such as physical changes upon storage and the effects of excipient grades as well as 
manufacturing techniques on drug cluster formation. 
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Summary  
Early stages of crystallization from amorphous solid dispersion (ASD) are typically not 
detected by means of standard methods like powder X-ray diffraction (XRPD). The aim of this 
study is therefore to evaluate if fractal analysis based on energy dispersive X-ray imaging can 
provide the means to identify early signs of physical instability. ASDs of the poorly water-
soluble compound, felodipine (FEL) were prepared by solvent evaporation using different 
grades of HPMCAS, at 50 wt% drug loading. Samples were stored at accelerated conditions of 
40 °C. Scanning electron microscopy equipped with an energy-dispersive X-ray spectroscopy 
(SEM-EDS) was used for elemental mapping of tablet surfaces. Comparative data were 
generated with a standard XRPD and with more sensitive methods for detection of early 
instability, i.e. laser scanning confocal microscopy (LSM) and atomic force microscopy 
(AFM). The SEM-EDS identified changes of drug-rich domains that were confirmed by LSM 
                                                      
R. Abreu-Villela, M. Schönenberger, I. Caraballo, and M. Kuentz, “Early stages of drug crystallization from 
amorphous solid dispersion via fractal analysis based on chemical imaging,” Eur. J. Pharm. Biopharm., vol. 133, 
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Chapter 5 
 
50 
and AFM. Early changes in drug clusters were also revealed by a multifractal analysis that 
indicated a beginning phase separation and drug crystallization. Therefore, the presented fractal 
cluster analysis based on chemical imaging bears much promise as a new method to detect 
early signs of physical instability in ASD, which is of great relevance for pharmaceutical 
development. 
5.1. Introduction  
Amorphous solid dispersion (ASD) has become an established oral delivery technique to 
formulate poorly water-soluble drugs [1][7][9]. Given the large number of papers that are 
published on solid dispersions, it is rather surprising that there are not many more of these 
products on the pharmaceutical market [115]. One of the main reasons is that ASDs are 
metastable systems and bear the risk of physical instability during their shelf life. Drug 
crystallization can occur depending on the history of an amorphous product and on given 
conditions [135]. Particularly critical is storage at elevated temperature and moisture leading 
eventually to phase separation and crystallization, which means a loss of biopharmaceutical 
advantages using ASD [14][72][73]. The molecular processes of phase separation as well as 
crystallization from amorphous material are complex and mobility in the glass state plays an 
important role. Relaxation of amorphous materials take place on different time scales from 
primary diffusive (α-relaxation) to secondary local relaxation such as Johari-Goldstein 
relaxations (β-relaxation). While α-relaxation becomes very slow in the glass state, it is mostly 
the secondary relaxations that are relevant for crystallization from amorphous state [11]–[13]. 
Once crystallization starts, it continues to reduce the system's free energy [15][74]. Thus, 
thermo- dynamics is the driver for physical change and molecular mobility is a facilitator, while 
surface effects can act as modulators, and heterogeneities as amplifiers of crystallization [18]. 
 A standard method to detect and characterize crystalline material is X-ray powder 
diffraction (XRPD) but like with other conventional methods such as differential scanning 
calorimetry, it is challenging to detect small amounts of crystalline material. Such small 
amounts can be already present following manufacture of an amorphous product or they are 
generated as initial instability but either ways, such crystallites can negatively affect kinetic 
stability of ASDs [15][74].  
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Interesting for detection of crystalline material are imaging techniques that can be based 
on different physical principles. Since amorphous formulations are typically multi-component 
systems, chemical image has the advantage that an active pharmaceutical ingredient (API) is 
differentiated from excipients. Any chemical imaging involves a sophisticated analytical 
technique for acquisition of images and spectra that contain the chemical information [21], 
which typically enables spatial distribution of one or all formulation components [22]. Images 
can be acquired at the surface and in the bulk by electron microscopy, such as, transmission 
electron microscopy (TEM) and scanning electron microscopy (SEM) with energy dispersive 
X-ray spectroscopy (EDS) [23][24]. Important are also vibrational spectroscopic techniques 
with appropriate optics, such as Raman [21][25][26], near infrared (NIR), or terahertz 
spectroscopy [15].  
It is critical for any imaging technique how the large amounts of data are evaluated. 
Suitable algorithms such as modern chemometric methods can be applied to extract useful 
information from otherwise just large and incomprehensible data sets [21]. An algorithmic 
topic in its own right is how clusters are analyzed in images since a naked eye is not capable 
of detecting any subtle changes of an imaged micro- structure. Promising for any such cluster 
analysis is fractal geometry. This approach was pioneered by Mandelbrot and does not use 
classical geometry to describe physical objects [28]. Fractal geometry has been applied in 
pharmaceutics, for example, to describe a solvent-mediated formation of a drug hydrate [89]. 
However, a single fractal dimension is often not sufficient to adequately describe a complex 
heterogeneous system. A more generalized mathematical concept is given by multifractal 
analysis, which decomposes the self-similar measures into intertwined fractal sets that describe 
the variations from the average in heterogeneous systems [40].  
Recently, the multifractal formalism was introduced in solid dispersion technology to 
describe the spatial distribution of an inorganic carrier [36]. In a subsequent work, the 
distribution of different drugs in ASDs was revealed to have a multifractal character [111]. The 
mathematical formalism was found to model adequately the heterogeneous nature of drug 
clusters in ASD and a next step would be to study changes over time. The hypothesis of the 
present work is that multifractal analysis based on chemical imaging can proof utility in 
analyzing early stages of physical instability. Thus, felodipine (FEL) was used as model drug 
in solid dispersions with the polymer hydroxypropyl methylcellulose acetate succinate 
(HPMCAS). The different grades LF and HF were used with 14–18% and 4–8% of succinoyl 
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substitutions, respectively [122]. ASDs of FEL/HPMCAS were analyzed topographically by 
SEM-EDS as a chemical imaging technique, which provided the basis for multifractal analysis. 
To have a comparison with other known sensitive methods, samples were also studied by laser 
scanning confocal microscopy (LSM) and atomic force microscopy (AFM). 
5.2. Materials and methods  
5.2.1. Materials  
Felodipine (FEL) was purchased from Kemprotec Ltd. (Smailthorn, Cumbria, UK) and 
the different grades of HPMCAS (Shin-Etsu AQOAT®, Type LF and HF) were a generous 
gift from Shin-Etsu Chemical Co. Ltd. (Tokyo, Japan). Dichloromethane and methanol (HPLC 
grade) were procured from Sigma-Aldrich (St. Louis, Missouri, USA). The API chemical 
structure, as well as monomer units of the polymer, are given in Fig. 10. Particularly 
highlighted are chloride atoms regarding their selective detection by energy dispersive X-ray 
spectroscopy. 
5.2.2. Methods 
5.2.2.1. Preparation of physical mixtures and solid dispersions by rotary evaporation  
Initial pretests of varying drug loads suggested that 50% FEL in polymer was rather 
challenging for amorphous stability, which therefore provided a suitable reference 
concentration in the ASDs of the main study. Binary mixtures of 50% w/w FEL polymer were 
Fig. 10. Chemical structures of felodipine (FEL) and HPMCAS. 
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then prepared by dissolving drug and polymer in a solvent mixture of 50:50 (v/v) di- 
chloromethane: methanol. All solvent mixtures were visually inspected to confirm that the drug 
and the polymer were completely dissolved, and the systems formed uniform one-phase 
solutions. The solvent was then removed at 50 °C under reduced pressure using a rotavapor 
RE120 (Bünchi Labortechnik AG, Flawil, Switzerland) with a vacuum controller CVC2 
(Vacuubrand GMBH+CO, Wertheim, Germany). The obtained solid mass was stored at room 
temperature overnight to re- move any residual solvents. The ASDs were freeze/milled with 
SPEX SamplePrep model 6770 (Metuchen, New jersey, USA). For a comparison with 
amorphous formulations, physical mixtures (PM) were pre- pared by mixing the powders of 
FEL and polymer for 5 min with a spatula. 
Samples of the solid dispersions were compressed to tablets for subsequent surface and image 
analysis. Thus, powders (100 mg) were manually fed into a hydraulic XP1 press (Korsch AG, 
Berlin, Germany) and manually compacted. The compacts were flat-faced and round with a 
diameter of 7 mm. 
5.2.2.2. X-ray powder diffraction  
X-ray powder diffractogram (XRPD) were determined for PM as well as for ASD 
obtained from rota-evaporation. A D2 Phaser diffractometer (Bruker AXS GmbH, Karlsruhe, 
Germany) was employed that was equipped with a Co-2K KFL diffraction tube configured and 
a 1D- Lynxeye detector and with a Fe filter. The applied voltage and current were 30 kV and 
10 mA, respectively. Diffraction patterns were obtained using a step width of 0.02° with a 
detector resolution in 2θ between 6 and 40° and a scan speed of 2 s/step at room temperature. 
5.2.2.3. Stability studies 
Compacts were stored in hermetically closed glass vials at a temperature of 40 °C using 
a climate chamber (Binder GmnH, Tuttlingen, Germany). The storage temperature was 
selected as a realistic but accelerating condition to detect kinetic changes over time (e.g. phase 
separation and/or drug crystallization). Samples were taken at specific time intervals and 
analyzed physically. 
5.2.2.4. Scanning electron microscopy and energy-dispersive X-ray spectroscopy  
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The samples were placed on double-sided adhesive carbon tabs and the surface of the 
compacts was coated with gold under argon vacuum with a Sputter Coater SC7620 (Quorum 
Technologies Ltd., Kent, UK). These surfaces were then studied by means of scanning electron 
microscopy (SEM) TM3030 PLUS (Hitachi High-Technologies Corporation, Tokyo, Japan) 
and micrographs were collected in a mix mode. The microscope was equipped with an energy-
dispersive X-ray spectroscopy (EDS) device for elemental mapping. The analysis was based 
on a Quantax 70 system software (Bruker Nano GmbH, Berlin, Germany) consisting of an X 
Flash Min SVE signal processing unit, a scan generator and Megalink interface together with 
an X Flash silicon drift detector 410/30H (Bruker Nano GmbH, Berlin, Germany). Samples 
were scanned during 300 s at a voltage of 15 kV to map the drug distribution of chloride (Cl) 
atoms for comparatively higher X-ray scattering intensity. This procedure was performed on 
all compacts at random location in spot sizes of 113×85 µm2. 
5.2.2.5. 3D-Laser scanning confocal microscopy 
Laser scanning micrographs of the sample surfaces were collected by means of a 3D laser 
scanning confocal microscopy (LSM) VK-X200 (Keyence, Osaka, Japan) using a violet laser 
(408 nm) and a 150x objective lens (Nikon Plan CF Apo, 150x/0.95, WD 0.2 mm). The surface 
is scanned at high speed in X, Y and Z, allowing image capturing and height measurements 
with high lateral resolution. Reflected white light and laser light emitted from the focal point 
are reflected back through the objective lens. The intensity of the laser light that passes through 
a pinhole is determined by a very sensitive 16-bit photomultiplier. Since the pinhole blocks 
most of the returning light (except the light from the focal point), confocal LSM delivers much 
sharper images than conventional microscopy techniques. In addition, a true color image from 
the integrated second light source is overlaid. 
5.2.2.6. Atomic force microscopy  
Atomic force microscopy (AFM) images of compacts were acquired at ambient 
conditions in dynamic AC mode using a NanoWizard 4 AFM instrument (JPK Instruments 
AG, Berlin, Germany). Height and phase images were collected simultaneously using a silicon 
PPP-NCHR cantilever (Nanosensors AG, Neuchâtel, Switzerland) with a resonance frequency 
of approximately 320 kHz and 42 Nm−1 spring constants. 
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5.2.2.7. Image processing  
The Cl distribution images were exported to Image J software (National Institutes of 
Health, Bethesda, Maryland, USA) and converted to maximum intensity projection. In a second 
step, the gray scale images in the bmp format (with 1023×766 pixels and a resolution 72 dpi) 
were resized to the png format with 512×512 pixels while keeping the same resolution. The 
projected images were unsharpened with a radius of 12 pixels and they were binarized using 
MATLAB software package, version R2017b (The MathWorks, Inc., Natick, USA). In a binary 
image, a signal pixel is defined as a digital element whose intensity is 1 after thresholding the 
images of 5 and this conversion to binary format (with a resolution of 96 dpi) was conducted 
with 10 images per each sample analysis. 
5.2.2.8. Multifractal and statistical data analysis  
While classical fractals are mathematical objects with a single fractal dimension, 
multifractal formalism decomposes self-similar measures into intertwined fractal sets [41]. A 
brief review of basic multifractal theory is given in the Appendix.  
Box-counting method algorithm was used to cover a 2-D image for determination of 
fractal dimensions. Using the binary images, boxes (grids of 512 pixel sizes) were counted 
using at least one pixel of the observed object. A multifractal spectrum was then determined 
with a customized MATLAB program as proposed and described previously [41].  
The formalism of multifractals expresses here a generalized fractal dimension or a 
“deformation parameter” of variability degrees (Dq) and moment order (q) that is a number 
within [−∞; +∞] interval extracting characteristics of the cluster distribution [39]. The 
multifractal spectra or the generalized dimension can be restricted to three values of particular 
interest D0, D1 and D2. Herein, D0 is the “classical box- counting dimension” also called the 
“capacity” dimension and D1 refers to an information dimension (related to Shannon’s measure 
of entropy) and characterizes the degree of disorder in a distribution. Finally, D2 is named a 
“correlation” dimension so it indirectly marks a degree of clustering [40] [41][43].  
The obtained fractal dimensions at the different time points were compared statistically 
by means of an analysis of the variance (ANOVA). STATGRAPHICS Centurion XVI ed. 
Professional (V. 16.1.15) from Statpoint Technologies Inc. (Warranton, Virginia, USA) was 
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used for all statistical calculations and a p-value < 0.05 was considered as significant. For 
comparison of the means, Fisher's procedure of the least significant difference (LSD) was 
calculated for 95% confidence intervals. 
 
5.3. Results  
5.3.1. Physical characterization  
XRPD is a standard method to detect crystalline material based on distinct peaks arising 
from Bragg scattering from defined crystal planes. The absence of diffraction peaks in the 
initial analysis of solid dispersions were therefore an indicator of successful amorphization of 
FEL at a comparatively high load of 50% (w/w). A subsequent storage during four weeks at 40 
°C did also not lead to samples in which crystalline drug was evidenced so the formulations 
were still unchanged at least based on XRPD (Fig. 11). By contrast, the analysis following 
eight weeks of storage (40 °C) revealed diffraction peaks of FEL, which was an obvious 
consequence of re-crystallization from the amorphous solid state. The diffraction peaks in the 
LF grade appeared to be more pronounced than in case of HF. 
 
Fig. 11. Powder X-ray diffraction of FEL in physical mixture (PM) with HPMCAS of different polymer grades and formulated 
as amorphous solid dispersion (ASD). From bottom to top: ASDs: FEL/HPMCAS-LF, FEL/HPMCAS-HF after 4 weeks stored 
at 40 °C; PM: FEL/HPMCAS-LF, FEL/HPMCAS-HF (all samples at a drug load of 50 wt% of FEL). 
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5.3.2. Scanning electron microscopy and energy-dispersive X-ray spectroscopy 
A suitable way to analyze the chemical distribution of specific atoms (as markers of 
molecules) on a surface is facilitated by SEM-EDS mapping. It is a qualitative method of 
chemical imaging and in this study, chloride was studied as characteristic marker of FEL since 
this was the only Cl-containing component in the formulation. The SEM-EDS binary 
micrographs of surface topography are presented in Fig. 12. Images of freshly prepared 
formulations and of those that show rearrangements of clusters over time (at 40 °C) are shown. 
The white pixels hold for the chloride (and hence FEL) distribution and it is possible to see 
some changes in the degree of clustering. However, only qualitative changes are detectable to 
a limited extent by the naked eye so that a more quantitative analysis is required to study cluster 
dynamics for which the multifractal formalism is applied. 
 
5.3.3. Multifractal analysis 
Table 4 shows the results of multifractal analysis in terms of the dimensions with q values 
from zero to two. The different Dq values were pointing to multifractals as a better model than 
to assume a simpler monofractal cluster distribution, which would entail a constant Dq. This 
was even more clearly seen when dimensions at any time point were plotted for a broader range 
Fig. 12. Results of energy dispersive X-ray spectroscopy (EDS) to obtain two-dimensional binary images of 
ASDs FEL/HPMCAS-LF, FEL/HPMCAS-HF (50 wt% of FEL), following storage at 40 °C. Drug-rich phase is 
shown as white domains. 
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of q values, as a typical sigmoidal shape was evidenced with decreasing Dq along decreasing 
q values (not shown). 
Table 4  
Generalized fractal dimensions of felodipine (FEL) solid dispersions over time as based on chemical 
imaging and conversion to binary pictures. 
 Age (weeks) Generalized fractal dimensions  
  D0 D1 D2 
FEL/HPMCAS-LF 0 1.92 ± 0.01 1.88 ± 0.01 1.81 ± 0.02 
(50:50) 2 1.92 ± 0.01 1.88 ± 0.01 1.81 ± 0.02 
 4 1.91 ± 0.01 1.86 ± 0.01 1.79 ± 0.01 
FEL/HPMCAS-HF 0 1.93 ± 0.00 1.89 ± 0.00 1.82 ± 0.01 
(50:50) 2 1.92 ± 0.01 1.88 ± 0.01 1.81 ± 0.02 
 4 1.91 ± 0.01 1.87 ± 0.02 1.80 ± 0.02 
 
The capacity dimension D0 was clearly below two for the Euclidian dimension but still 
comparatively high suggesting rather dense fractal structures. Values for D1 and D2 were also 
in a similar range as compared to our previous study [25]. The changes over time were focused 
on the early stage of stability testing, which did not reveal recrystallization based on classical 
XRPD testing. However, Table 4 indicates some changes of Dq over time, which were 
statistically analyzed. An analysis of the variance (ANOVA) was conducted with time and 
polymer grade as factors and the generalized fractal dimensions (D0, D1, and D2) were indeed 
found to be statistically significant to capture the microstructure changes, with significant p-
values (p < 0.0001) for a time effect regarding any of the three dimensions studied. By contrast, 
the factor of HPMCAS grade was not found to be significant with respect to D0, D1, or D2. Fig. 
13 shows a statistical means plot together with Fisher's 95% LSD intervals. The significant 
storage effect was similar in extent for all fractal dimensions and is shown in Fig. 13 for D0 as 
well as for D2. The novel approach was obviously capable of identifying microstructural 
changes even in the early phase of stability testing. 
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5.3.4. Laser scanning confocal microscopy  
LSM provided nondestructive images in a relatively broad microstructural range for the 
different time points of early stability testing of FEL systems. Fig. 14 shows rather rough 
surfaces before storage (Fig. 14a/b) with hardly any crystals observed. Interestingly, the LSM 
images after 4 weeks (Fig. 14c/d) suggested generally smoother surfaces with some curved 
rough regions in the underlying microstructure for both formulations. Either for each system, 
a “blooming” effect was evidenced, which could be interpreted as crystals formed on top of 
the surface or protruding directly underneath the surface. Crystals and aggregations thereof 
were seen significantly in the system of FEL/HPMCAS-LF (Fig. 14c), but also from beneath 
and on top of the surface in the formulation of FEL/HPMCAS-HF (Fig. 14d). In general, LSM 
suggested occurrence of some crystals at early stability time (4 weeks, 40 °C). 
5.3.5. Atomic force microscopy  
Atomic force microscopy (AFM) is another physical surface analysis method that reaches 
small fields of view in a submicron range and is therefore complementary to LSM as a 
reference method of early stability testing. 
 
Fig. 13. Statistical means plot of FEL/HPMCAS ASD formulations (50 wt% of FEL) based on a two-factor ANOVA of 
how D0 (a) and D2 (b) are affected by storage time (at 40 °C), and intervals of Fisher's Least Significant Difference 
(LSD, 95%) are shown. 
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AFM topography (3D height) measurements were carried out to understand the 
morphology and growth dynamics of the surface before and after storage. The representative 
micrographs are visible in Fig. 15. The initial images show maximum height values of 100 nm 
(Fig. 15a) and 160 nm (Fig. 15b), respectively. Brighter islands or domain regions, most likely 
corresponding to FEL-rich domains surrounded by HPMCAS-rich domains, are indicated by 
peaks. The round edges of the FEL-rich domains indicate most likely that the aggregated 
clusters were still coated with polymer; therefore, minor phase contrast can be differentiated 
among these surfaces (Fig. 16a, b). These results are in line with previous literature [137]. AFM 
phase images were recorded to obtain a contrast due to variation in energy dissipation, which 
is related to the presence of differences in surface adherence and consequently different 
material properties. This technique also allows detecting localized variations in stiffness, so 
even more details of morphology can be obtained by phase contrast. Initial samples illustrate 
that the surfaces have a homogeneous contrast with brighter and darker regions co-existing 
Fig. 14. Confocal laser microscopy of ASDs before storage (a, b) and after storage (c, d) for 4 weeks at 40 °C. 
FEL/HPMCAS-LF (a, c), FEL/HPMCAS-HF (b, d), at 50 wt % of FEL. 
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on the surface (Fig. 16a/b); hence material differences are less pronounced, assuming that the 
polymer is dominating and/or amorphous domains of the drug prevail upon crystal growth. 
Fig. 16. AFM topographical images of FEL/HPMCAS ASDs before storage (a, b) and after storage (c, d) for 4 weeks 
at 40 °C. FEL/HPMCAS-LF (a, c) and FEL/HPMCAS-HF (b, d). 
Fig. 16. AFM phase images of FEL/HPMCAS ASDs; before (a, b) and after storage (c, d) for 4 weeks 
at 40 °C. FEL/HPMCAS-LF (a, c) and FEL/HPMCAS-HF (b, d). 
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On the other hand, after storage at accelerated conditions for 4 weeks, the surface 
topography (Fig. 15c/d) shows a tendency to generally smoother (the height scale dropped to 
14 nm and 30 nm, respectively), but more heterogeneous surfaces in the sense of growing phase 
separation as seen in the phase contrast images (Fig. 16c/d).  
Both AFM modes (topography and phase imaging) strongly support each other and verify 
the obtained results giving a very detailed insight into the nanoscopic morphology of the 
specimen. 
5.4. Discussion 
The metastable character of ASD is a hurdle for their development because re-
crystallization during long-term stability testing is a critical setback on the way to bring a drug 
product on the market. It is particularly critical when such physical instability is only detected 
late in pharmaceutical development, whereas an early identification of kinetically unstable 
formulations is less problematic in a screening phase. Accordingly, there is a tremendous 
interest in early identification of drug phase separation and re-crystallization from amorphous 
state. The present work is based on the hypothesis that multifractals can be helpful to early 
detect instability in amorphous drug formulations. The selected model systems showed some 
physical changes after four weeks with likely initial phase separation and occurrence of first 
crystals at the time of four weeks where XRPD still could not detect any changes. It was in line 
with expectation that LSM and AFM were more sensitive methods than XRPD to capture 
changes so these reference methods were interesting to compare with the novel multifractal 
approach based on SEM-EDS imaging.  
As a result, differences in the multifractal dimensions D0, D1, and D2 were indeed 
evidenced after one month compared to the initial analysis. Therefore, multifractals were 
capable of revealing microstructural changes caused by instability that were otherwise hard to 
identify from the original images of SEM-EDS and that were undetected by XRPD. Like any 
chemical imaging technique, SEM-EDS comes with spatial resolution limits and they impact 
on the determined clusters [139]. Such clusters hold for drug-rich domains and it is not possible 
to directly infer their physical state. These drug-rich regions can be of different kinds [133], 
e.g. concentrated drug associated with polymer or it can be separate amorphous drug domains 
considered in the binary images. Changes in these clusters are primarily changes in 
mathematical objects as captured by the fractal dimensions, D0, D1, and D2. The physical 
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interpretation of these clusters should be always in the context of the applied imaging method. 
Since the multifractal dimensions provide meaning to cluster distributions, they can prove 
helpful for understanding any early changes in ASD as well as small crystal nuclei. This is 
important to keep in mind when clusters of drug are The dimension D0 describes a space-filling 
capacity [105] and values decreased in the early period of stability testing. This result was not 
easy to predict because there are different possible processes like drug migration to the surface 
that may increase the space-filling capacity. An increase could also come from drug that was 
previously too dispersed and low concentrated to be detected as a drug-rich domain so that 
local aggregation can lead to new clusters. While these are processes to in- crease D0, there are 
other effects leading to lowered values of this capacity dimension. Some of the drug-rich 
domains of drug-polymer aggregates may locally become more concentrated in an overall 
phase separation or drug re-crystallization. The resulting more concentrated clusters would 
appear still white in the binary images so that overall space coverage could slightly diminish.  
The different cluster changes were apparently also leading on the average to a reduction 
in the information dimension D1. This dimension reflects the diversity of elements in the 
system [42][78]. Moreover, D2 holds for a correlation dimension [42][43][79] and the 
evidenced re- duction was caused by the microstructural changes. Thinking of the 
transformation from amorphous clusters to crystals there is of course nucleation as well as 
growth. Depending on which mechanism prevails, there would be different ways of how the 
correlation dimension changes. Thinking of the microstructural processes of phase separation, 
or crystal nucleation and growth, it is possible that different processes affect fractal dimensions 
in opposite directions, which could entail a loss of discrimination. The sensitivity to detect 
early physical instability by the multifractal approach is therefore certainly depending on the 
physical processes that occur as well as on the imaging technique used.  
To compare the changes in cluster dynamics with other physical analysis methods, the 
sample surfaces were also studied by means of LSM and AFM. LSM and AFM are popular 
microscopic techniques to study surfaces with ultrahigh resolution [80][81]. While LSM can 
sample comparatively larger surfaces, AFM provides sub-micron images of surface topography 
and phase imaging.  
The initial LSM micrograph profiles (Fig. 14a/b) of the surfaces were rather uneven and 
rough and both formulations had rather similar surface texture while hardly no crystals were 
seen. Compared to the initial rough micrographs, it is evident in Fig. 14c/d that there was a 
structural re-arrangement of the surface suggested likely caused by increased mobility [144]. 
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The surfaces revealed in both formulations flat and smooth areas, and curved rough regions in 
the underlying micro- structure. It is suggested that after the storage at 40 °C, the temperature 
induced possible re-crystallization and aggregates of drug were formed, as can be observed, 
small groups of crystals with regular shape grow towards the surface as a result of re-
crystallization.  
Due to the small area of analysis, AFM was leading to an individual view on a sub-
micron scale. The initial roughness is confirmed with a continuous matrix where critical spots 
of drug-rich domains might be occasionally recognized (Fig. 15a/b), while after storage the 
topography of the surfaces looked generally a bit smoother (Fig. 15c/d). From phase imaging, 
it is suggested that initially (Fig. 16a/b) the drug and the polymer were remaining both in the 
amorphous state and showed more or less homogenous contrast in the phase signal. The 
appearance of a brighter domain in the AFM phase image (Fig. 16c) gives evidence of the 
existence of crystalline domains among partially amorphous and highly dissipating polymer 
regions, indicating a heterogeneous surface due to the phase separation. These findings seem 
contradictory at first sight, but under the assumption that amorphous regions of the drug are re- 
crystallizing with accelerating temperature, the polymer needs to re- organize as well and starts 
to flatten out. This is in agreement with the relaxation phenomenon and mobility in glass state 
[18].  
The orthogonal techniques LSM and AFM would be in line with the assumption that 
crystalline-amorphous phase separation may have occurred [133]. Based on this mechanism, a 
larger amount of drug can uniformly de-mix and segregate in a short amount of time, while 
nucleation and growth act only locally [145]. The de-mixing was likely to accelerate re-
crystallization of drug.  
In summary, the finding of the orthogonal methods of SEM-EDS, LSM and AFM suggest 
that even the freshly prepared solid dispersions had drug- rich and polymer-rich clusters and 
this heterogeneity was reflected in the binary images obtained from SEM-EDS. The subsequent 
dynamics of de mixing and re-crystallization was captured as complex changes in cluster 
dynamics of the binary images leading to measurable changes in multi- fractal dimension, LSM 
and AFM images, whereas in the classical XRPD analysis no changes were observed 
throughout the same time period. 
5.5. Conclusions  
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The present work addressed the need for novel tools in early identification of physical 
instability of solid dispersions. Multifractal analysis was introduced successfully to early stages 
of stability testing using amorphous solid dispersions. Changes in the fractal dimensions 
were noted early in stability testing, when no changes were appreciated based on XRPD 
analysis. The orthogonal techniques of SEM-EDS, LSM and AFM that are known to be 
sensitive for microstructural change, suggested that the initial solid dispersions already 
displayed heterogeneity in terms of drug-rich and polymer-rich domains and de- mixing of the 
components was likely to precede nucleation of crystal- line material.  
A decrease of the fractal dimensions D0, D1 and D2 was statistically significant after four 
weeks of stability testing, while a possible effect of the HPMCAS grade was not revealed. 
Although the use of multifractals was successful for early instability detection, care is needed 
to expect the same cluster dynamics in other solid dispersions too. We discussed that different 
mechanisms of microstructural change can affect clusters and therefore fractal dimensions. 
However, a clear strength of the presented data evaluation is that this cluster analysis can be 
based even on more than one physical method of imaging. It could be, for example, also used 
for imaging based on Raman or near infrared spectroscopy. 
Moreover, it would be interesting to study different types of solid dispersions. The 
present work holds much promise, but further research is needed to better assess the capability 
of multifractals to act as early warning tool for physical changes in metastable drug 
formulations. 
 
Appendix A 
Multifractal theory 
 
The fractal dimension is measured by overlaying the binary image with grid of boxes and 
counting the number of boxes, N (), this is expressed as [40][41] 
𝑁(𝜀)~𝜀−𝐷0  (1)  
where D0 is the fractal dimension, calculated from the following equation: 
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𝐷0 = 𝜀→0
𝑙𝑖𝑚 log 𝑁(𝜀)
log
1
𝜀
  (2) 
D0 is derived by counting the number of boxes with various sizes to cover the image and then 
estimating the linear region in the log-log plot. However, complex structures may not entirely 
be described by single fractal dimension, but by multifractal analysis, which considers the 
amount of mass inside each box, in this way characterize these complex structures. The 
probability Pi of finding the object pixel in the ith box is determined by 
 𝑃𝑖(𝜀)~𝜀
𝛼𝑖  (3) 
where αi is the singularity strength which corresponds to the density in the ith box. 
The probability distribution for multifractal measurements is 
∑ [𝑃𝑖(𝜀)𝑞]𝑖  ~𝜀
𝜏(𝑞) (4) 
Where q is the exponent expressing the fractal properties in different scales of the object. 𝜏(q) can be 
defined as:  
𝜏(𝑞) =  lim
𝑟→0
[ln ( ∑ 𝑃𝑖𝑖 (𝜀)
𝑞)] ln(1/𝜀)⁄       (5) 
The full plot of Dq versus q is representative of the strength of the multifractality of finite measure, and 
the generalized dimension Dq which is related with q can be expressed as 
𝐷𝑞 =  
𝜏(𝑞)
(𝑞 − 1)⁄   (6) 
Also, the relationship between parameters of f(α) versus α are used to calculate the multifractal spectra: 
𝑁(𝛼)~ 𝜀−𝑓(𝛼)  (7) 
where the number of boxes N(α) for each probability Pi (Ɛ) has singularity strengths between α and α + 
dα is found to scale.  f (α) against α, in general way it gives the “fractal dimension” f (α) of sets where 
the measure scales locally with the same exponent α. The multifractal spectrum gives one dimension 
for each set where the data scales similarly. The variable f (α(q)) gives the local fractal dimension at 
resolution q.  f(α) has the same information of generalized information Dq and can be defined as [39]–
[41]: 
𝑓(𝛼(𝑞)) = 𝑞𝛼(𝑞) −  𝜏(𝑞)  (8) 
Chapter 5 
 
67 
where α(q) can be defined as: 
𝛼(𝑞) =
𝑑𝜏(𝑞)
𝑑𝑞 ⁄  (9) 
In case of monofractal, D0= D1= D2, whereas different values D0 ≥  D1≥  D2  indicate a 
multifractal system [39].
  
 
Chapter 6 
 
Final remarks and outlook 
 
 
Great strides have been made in formulation and process design of ASD. However, 
despite diverse successes and a wealth of generated information, there are further 
improvements that could be still made to accelerate development and enhance performance of 
ASDs. The present thesis focused on the application of fractal geometry to such solid 
dispersions. Thus, fractal dimensions were assigned to a heterogeneous structure that were 
observed from chemical imaging. The findings and insights into the microstructure enabled a 
better process understanding and can help with decision making during formulation 
development. 
Chemical imaging together with the multifractal approach proved to be reproducible and 
robust. This was suggested by the results obtained from microstructural imaging of different 
drug types and varying concentrations. The changes after the addition of an additive such as 
urea, showed clear effects on the different fractal dimensions. The study of the structural 
insights helped to better understand the performance of an ASD and may be used in the future 
also for another type of pharmaceutical dosage form. In this way the multifractal approach 
bears much promise from a theoretical as well as practical perspective.  
This thesis also presents the need for novel tools in early identification of physical 
instability of solid dispersions. Multifractal analysis was introduced successfully to early stages 
of stability testing using ASD. Changes in the fractal dimensions were evidenced early in 
stability testing, when no changes were appreciated based on a comparative XRPD analysis. 
Although the use of multifractals was successful for early instability detection, care is needed 
to expect the same cluster dynamics in other solid dispersions too. We discussed that different 
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mechanisms of microstructural change can affect clusters and therefore fractal dimensions. 
However, a clear strength of the presented data evaluation is that this cluster analysis can be 
based even on more than one physical method of imaging. 
It is also presented in this thesis that a microstructural study based on fractal geometry 
was helpful regarding the method selection for preparation of ASD. The influence was 
investigated by comparing different manufacturing techniques, such as: solvent 
coprecipitation, solvent evaporation and fusion method, while keeping the same drug loading. 
It was concluded that the fusion method was the best manufacturing technique for the systems 
studied, proving the importance of heating for this model system. The multifractal approach 
provided an effective characterization of the microstructure obtained from the different 
manufacturing technologies. 
In general, this thesis presents an effective data evaluation approach based on imaging to 
obtain structural insights from ASDs. The different applications from early stability testing to 
study of microstructural differences cause by excipients, drug load and processes appear to be 
highly attractive from a development as well as manufacturing viewpoint. Therefore, the 
multifractal approach bears a strong potential to improve microstructural understanding, which 
is beneficial especially in Quality by Design framework and can be harnessed in the future also 
for other dosage forms and other underlying imaging techniques than used in this study. 
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